JAK/STAT Signaling

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6).

JAKs are an integral component of the receptor subunit with very little release or exchange into the cytoplasm and as such are located primarily at the plasma membrane. STAT has seven conserved features: an N-terminal domain (NT), a coiled-coil domain (CC), a central DNA-binding domain (DBD), a linker region, an SH2 domain followed by a single conserved tyrosine residue, and a C-terminal transactivation domain (TAD). JAK phosphorylation of the STAT proteins then results in a spatial reorganisation of the dimer complex, and translocates to the nucleus. Once in the nucleus, STAT dimmers are stabilised by NT:NT interactions and bind cooperatively to tandem sequence elements within promoter regions to activate the transcription of specific gene subsets.

Aberrant activation of the JAK/STAT pathway has been reported in a variety of diseases, including inflammatory conditions, hematologic malignancies, and solid tumors. More recently, human myeloproliferative neoplasms are discovered to be associated with a unique acquired somatic mutation in JAK2 (JAK2 V617F), rare exon 12 JAK2 mutations, or thrombopoietin receptor mutations that constitutively activate wild-type JAK2. As a result, several drug companies have begun to develop therapeutics that inhibit the function of JAK tyrosine kinases. Currently, several JAK-targeting drugs have been used in the clinic for treating diseases including rheumatoid arthritis and myeloproliferative.

References:

[1] Kiu H, et al. Growth Factors. 2012 Apr;30(2):88-106.
[2] Quintás-Cardama A, et al. Clin Cancer Res. 2013 Apr 15;19(8):1933-40.
[3] Villarino AV, et al. J Immunol. 2015 Jan 1;194(1):21-7.
[4] Vainchenker W, et al. Oncogene. 2013 May 23;32(21):2601-13.



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Target List in JAK/STAT Signaling

EGFR

Epidermal growth factor receptor; ErbB-1; HER1

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras-mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3 kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C-protein kinase C (PLC-PKC) pathways.

(E)-AG 556

((E)-Tyrphostin AG 556) Cat. No.: HY-101041

(E)-AG 556 is a highly selective **EGFR** inhibitor and also blocks LPS-induced TNF-α production.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E)-AG 99

((E)-Tyrphostin 46; (E)-Tyrphostin AG 99) Cat. No.: HY-100962

(E)-AG 99 ((E)-Tyrphostin 46) is a potent **EGFR** inhibitor.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

(E/Z)-AG490

((E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42) Cat. No.: HY-107459

(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a **tyrosine kinase** inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-CP-724714

Cat. No.: HY-W008914

(E/Z)-CP-724714 is a racemic compound of (E)-CP-724714 and (Z)-CP-724714 isomers. CP-724714 is a potent and selective orally active ErbB2 (HER2) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

(Rac)-JBJ-04-125-02

Cat. No.: HY-135805A

(Rac)-JBJ-04-125-02 is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active **EGFR** inhibitor with an IC_{50} of 0.26 nM for $EGFR^{L858R/T790M}$.



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg

(Rac)-Pyrotinib

((Rac)-SHR-1258) Cat. No.: HY-104065A

(Rac)-Pyrotinib ((Rac)-SHR-1258) is the racemate of Pyrotinib. Pyrotinib is a potent and selective EGFR/HER2 dual inhibitor.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

(S)-Sunvozertinib

((S)-DZD9008) Cat. No.: HY-132842A

(S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against **EGFR** exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC_{50}=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively).



Purity: 99.14%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AEE788

(NVP-AEE 788) Cat. No.: HY-10045

AEE788 is an inhibitor of the **EGFR** and **ErbB2** with IC_{50} values of 2 and 6 nM, respectively.



Purity: 98.39%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AEE788-d5

Cat. No.: HY-10045S

AEE788-d5 is the deuterium labeled AEE788. AEE788 is an inhibitor of the **EGFR** and **ErbB2** with IC_{50} values of 2 and 6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Afatinib

(BIBW 2992) Cat. No.: HY-10261

Afatinib (BIBW 2992) is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.93%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Afatinib D6

(BIBW 2992 D6) **Cat. No.:** HY-10261S

Afatinib D6 (BIBW 2992 D6) is deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Afatinib dimaleate

(BIBW 2992MA2) **Cat. No.:** HY-10261A

Afatinib dimaleate is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Afatinib impurity 11

Cat. No.: HY-133780

Afatinib impurity 11 is an impurity of Afatinib. Afatinib is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Afatinib-d4

(BIBW 2992-d4) **Cat. No.:** HY-10261S1

Afatinib-d4 (BIBW 2992-d4) is the deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Afatinib-d6 dimaleate

(BIBW 2992MA2-d6) **Cat. No.:** HY-10261AS

Afatinib-d6 dimaleate (BIBW 2992MA2-d6) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible **EGFR** family inhibitor with IC_{50}s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for $EGFR^{wt}$, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$ and HER2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG 555

(Tyrphostin AG 555) **Cat. No.:** HY-15336

AG 555 (Tyrphostin AG 555), a potent antiretroviral drug, is a potent and selective inhibitor of **EGFR** and blocks **Cdk2** activation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg

AG-1478

(Tyrphostin AG-1478; NSC 693255) **Cat. No.:** HY-13524

AG-1478 (Tyrphostin AG-1478) is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM. AG-1478 has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride; NSC 693255 hydrochloride)

Cat. No.: HY-13524A

AG-1478 hydrochloride (Tyrphostin AG-1478 hydrochloride) is a selective **EGFR** tyrosine kinase inhibitor with IC_{50} of 3 nM. AG-1478 hydrochloride has antiviral effects against **HCV** and **encephalomyocarditis virus (EMCV)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AG-494

(Tyrphostin AG 494) **Cat. No.:** HY-101042

AG-494 (Tyrphostin AG 494) is a potent and selective **EGFR** tyrosine kinase inhibitor (IC_{50}=0.7 μM). AG-494 inhibits the autophosphorylation of EGFR, ErbB2, HER1-2 and PDGF-R with IC_{50}s 1.1, 39, 45 and 6 μM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

AG-825

(Tyrphostin AG-825) **Cat. No.:** HY-15844

AG-825 (Tyrphostin AG-825) is a selective and ATP-competitive **ErbB2** inhibitor which suppresses tyrosine phosphorylation, with an IC_{50} of 0.35 μM. AG-825 displays anti-cancer activity. AG825 significantly accelerates apoptosis of human neutrophils.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AG1557

Cat. No.: HY-12806

AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (**EGFR**) tyrosine kinase, has a **pIC$_{50}$** value of 8.194.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AG490

(Tyrphostin AG490; Tyrphostin B42) Cat. No.: HY-12000

AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Alflutinib

(Furmonertinib; AST2818) Cat. No.: HY-112870

Alflutinib is a potent inhibitor of **EGFR**. Alflutinib inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Alflutinib mesylate

(Furmonertinib mesylate; AST2818 mesylate) Cat. No.: HY-112870A

Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of **EGFR**. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation.



Purity: 99.96%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 50 mg, 100 mg

Allitinib

(AST-1306; ALS 1306) Cat. No.: HY-15375

Allitinib (AST-1306) is an orally active and irreversible **EGFR** and **ErbB2** inhibitor with **IC$_{50}$**s of 0.5 and 3 nM, respectively. Allitinib also inhibits **ErbB4** with an IC$_{50}$ of 0.8 nM. Allitinib is an anilino-quinazoline compound and has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Allitinib tosylate

(AST-1306 (TsOH)) Cat. No.: HY-13427

Allitinib tosylate (AST-1306 (TsOH)) is an orally active and irreversible **EGFR** and **ErbB2** inhibitor with **IC$_{50}$**s of 0.5 and 3 nM, respectively. Allitinib tosylate also inhibits **ErbB4** with an IC$_{50}$ of 0.8 nM.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Almonertinib

(HS-10296) Cat. No.: HY-112823

Almonertinib (HS-10296) is an orally available, irreversible, third-generation **EGFR tyrosine kinase** inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Almonertinib hydrochloride

(HS-10296 hydrochloride) Cat. No.: HY-112823B

Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation **EGFR tyrosine kinase** inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations.



Purity: 98.03%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Almonertinib mesylate

(HS-10296 mesylate) Cat. No.: HY-112823A

Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation **EGFR** tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ARRY-380 analog

Cat. No.: HY-10531

ARRY-380 analog, an inhibitor of **EGFR (ErbB1)**, is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2.



Purity: 96.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ARRY-380 analog-d3

Cat. No.: HY-10531S



ARRY-380 analog-d3 is the deuterium labeled ARRY-380 analog. ARRY-380 analog, an inhibitor of **EGFR (ErbB1)**, is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2.

Purity: >98%
Clinical Data: No Development Reported
Size: 25 mg

ASK120067

Cat. No.: HY-138751



ASK120067 is a potent and orally active inhibitor of **$EGFR^{T790M}$** (IC_{50}:0.3 nM) with selectivity over $EGFR^{WT}$ (IC_{50}:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC).

Purity: 98.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AST5902 trimesylate

Cat. No.: HY-138627A



AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an **EGFR** inhibitor.

Purity: 99.87%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Astragaloside VI

Cat. No.: HY-N6577



Astragaloside VI could activate **EGFR/ERK** signalling pathway to improve wound healing.

Purity: 99.95%
Clinical Data: No Development Reported
Size: 5 mg

AV-412

(MP412)

Cat. No.: HY-10346



AV-412 (MP412) is an **EGFR** inhibitor with IC_{50}s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, $EGFR^{L858R}$, $EGFR^{T790M}$, $EGFR^{L858R/T790M}$ and ErbB2, respectively.

Purity: 99.17%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AV-412 free base

(MP-412 free base)

Cat. No.: HY-10346A



AV-412 free base (MP-412 free base) is an **EGFR** inhibitor with IC_{50}s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, $EGFR^{L858R}$, $EGFR^{T790M}$, $EGFR^{L858R/T790M}$ and ErbB2, respectively.

Purity: 98.07%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Avitinib

(Abivertinib; AC0010)

Cat. No.: HY-19816



Avitinib (AC0010) is an irreversible, mutant-selective **EGFR** inhibitor that effectively inhibits EGFR T790M resistance mutations in non-small cell lung cancer (NSCLC). Abivertinib is also a novel **BTK** inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Avitinib maleate

(Abivertinib maleate; AC0010 maleate)

Cat. No.: HY-19816A



Avitinib (Abivertinib) maleate is a pyrrolopyrimidine-based irreversible epidermal growth factor receptor (**EGFR**) inhibitor with an IC_{50} of 7.68 nM.

Purity: 99.17%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZ-5104

Cat. No.: HY-B0793



AZ-5104 is an active, demethylated metabolite of AZD 9291. AZ-5104 is an **EGFR** inhibitor with IC_{50}s of 1, 6, 1, 25 and 7 nM for $EGFR^{L858R/T790M}$, $EGFR^{L858R}$, $EGFR^{L861Q}$, EGFR and ErbB4, respectively.

Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AZ7550

Cat. No.: HY-B0794



AZ7550 is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ7550 hydrochloride

Cat. No.: HY-B0794A

AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 98.66%
Clinical Data: Phase 1
Size: 5 mg, 10 mg

AZ7550 Mesylate

(AZ7550 trimesylate salt)

Cat. No.: HY-B0794B

AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of **IGF1R** with an IC_{50} of 1.6 μM.



Purity: 99.34%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg

BAY 2476568

Cat. No.: HY-134877

BAY 2476568 is a potent and selective **EGFR** inhibitor, with IC_{50}s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Befotertinib

(D-0316)

Cat. No.: HY-137433

Befotertinib (D-0316) is the third-generation **EGFR tyrosine kinase** inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).



Purity: 99.96%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BGB-102

(JNJ-26483327)

Cat. No.: HY-15732

BGB-102 is a potent multi-kinase inhibitor against **EGFR**, **HER2**, and **HER4** with IC_{50}s of 9.6 nM, 18 nM and 40.3 nM, respectively.



Purity: 97.10%
Clinical Data: Phase 1
Size: 5 mg

BI-4020

Cat. No.: HY-129550

BI-4020 is a fourth-generation, orally active, and non-covalent **EGFR** tyrosine kinase inhibitor.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BLU-945

Cat. No.: HY-144680

receptor (**EGFR**). EGFR is a member of the erbB receptor family, which includes transmembrane protein tyrosine kinase receptors. BLU-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

BMS-599626

(AC480)

Cat. No.: HY-10251

BMS-599626 (AC480) is a selective and orally bioavailable **HER1** and **HER2** inhibitor, with IC_{50}s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC_{50}=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

BMS-599626 Hydrochloride

(AC480 Hydrochloride)

Cat. No.: HY-12010

BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable **HER1** and **HER2** inhibitor, with IC_{50}s of 20 and 30 nM, respectively.



Purity: 99.87%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 50 mg, 100 mg

BMS-690514

Cat. No.: HY-10333

BMS-690514 is a potent and orally active inhibitor of **EGFR** and **VEGFR**; has IC_{50}s of 5, 20 and 60 nM for EGFR, HER 2 and HER 4, respectively.



Purity: 99.89%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Butein

(2′,3,4,4′-tetrahydroxy Chalcone)

Cat. No.: HY-16558

Butein is a cAMP-specific **PDE** inhibitor with an IC_{50} of 10.4 μM for **PDE4**. Butein is a specific protein tyrosine kinase inhibitor with IC_{50}s of 16 and 65 μM for **EGFR** and **p60**$^{c\text{-}src}$ in HepG2 cells.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Canertinib

(CI-1033; PD-183805)

Cat. No.: HY-10367

Canertinib (CI-1033;PD-183805) is a potent and irreversible **EGFR** inhibitor; inhibits cellular **EGFR** and **ErbB2** autophosphorylation with IC_{50}s of 7.4 and 9 nM.



Purity: 99.95%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Canertinib dihydrochloride

(CI-1033 dihydrochloride; PD-183805 dihydrochloride)

Cat. No.: HY-10367A

Canertinib dihydrochloride (CI-1033 dihydrochloride) is a potent and irreversible **EGFR** inhibitor; inhibits cellular **EGFR** and **ErbB2** autophosphorylation with IC_{50}s of 7.4 and 9 nM.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

CCT365623 hydrochloride

Cat. No.: HY-124674A

CCT365623 hydrochloride is an orally active **lysyl oxidase (LOX)** inhibitor, with an IC_{50} of 0.89 μM. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is extremely well tolerated, and has good pharmacokinetic properties.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cetuximab

(C225)

Cat. No.: HY-P9905

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (**EGFR**), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

Cetuximab

Purity: 99.70%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

CGP52411

(DAPH)

Cat. No.: HY-103442

CGP52411 (DAPH) is a high selective, potent, orally active and ATP-competitive **EGFR** inhibitor with an IC_{50} of 0.3 μM.



Purity: 99.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

CHMFL-EGFR-202

Cat. No.: HY-101522

CHMFL-EGFR-202 is a potent, irreversible inhibitor of **epidermal growth factor receptor (EGFR) mutant kinase**, with IC_{50}s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Chrysophanol

(Chrysophanic acid)

Cat. No.: HY-13595

Chrysophanol (Chrysophanic acid) is a natural anthraquinone, which inhibits EGF-induced phosphorylation of **EGFR** and suppresses activation of **AKT** and **mTOR/p70S6K**.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 50 mg, 100 mg

CL-387785

(EKI-785; WAY-EKI 785)

Cat. No.: HY-10325

CL-387785(EKI785; WAY-EKI 785) is an irreversible inhibitor of **EGFR** with IC_{50} of 370 pM.



Purity: 98.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CNX-2006

Cat. No.: HY-13897

CNX-2006 is a mutant-selective and irreversible **EGFR** inhibitor with an IC_{50} below 20 nM for EGFR^{T790M}.



Purity: 99.68%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CP-724714

Cat. No.: HY-14674

CP-724714 is a potent, selective and orally active **ErbB2 (HER2)** tyrosine kinase inhibitor, with an IC_{50} of 10 nM. CP-724714 displays a marked selectivity against EGFR kinase (IC_{50}=6400 nM). CP-724714 potently inhibits ErbB2 receptor autophosphorylation in intact cells.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CUDC-101

Cat. No.: HY-10223

CUDC-101 is a potent inhibitor of **HDAC**, **EGFR**, and **HER2** with IC_{50}s of 4.4, 2.4, and 15.7 nM, respectively.



Purity: 99.19%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Cyasterone

Cat. No.: HY-N0211

Cyasterone, a natural **EGFR** inhibitor, mainly isolated from Ajuga decumbens Thunb (Labiatae). Cyasterone manifests anti-proliferation effect by induced **apoptosis** and cell cycle arrests. Cyasterone may serves as a therapeutic anti-tumor agent against human tumors.



Purity: 98.70%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

Dacomitinib

(PF-00299804; PF-299804)

Cat. No.: HY-13272

Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the **ERBB** family of kinases with IC_{50}s of 6 nM, 45.7 nM and 73.7 nM for **EGFR**, **ERBB2**, and **ERBB4**, respectively.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dacomitinib-d10

(PF-00299804-d10; PF-299804-d10)

Cat. No.: HY-13272S3

Dacomitinib-d10 is deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the ERBB family of kinases with IC50s of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dacomitinib-d10 dihydrochloride (PF-00299804-d10 dihydrochloride; PF-299804-d10 dihydrochloride)

Cat. No.: HY-13272S2

Dacomitinib-d10 (PF-00299804-d10) dihydrochloride is the deuterium labeled Dacomitinib dihydrochloride.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dacomitinib-d3

(PF-00299804-d3; PF-299804-d3)

Cat. No.: HY-13272S

Dacomitinib-d3 (PF-00299804-d3) is the deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the **ERBB** family of kinases with IC_{50}s of 6 nM, 45.7 nM and 73.7 nM for **EGFR**, **ERBB2**, and **ERBB4**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Dacomitinib-d5

(PF-00299804-d5; PF-299804-d5)

Cat. No.: HY-13272S1

Dacomitinib-d5 (PF-00299804-d5) is the deuterium labeled Dacomitinib. Dacomitinib (PF-00299804) is a specific and irreversible inhibitor of the **ERBB** family of kinases with IC_{50}s of 6 nM, 45.7 nM and 73.7 nM for **EGFR**, **ERBB2**, and **ERBB4**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Daphnetin

(7,8-Dihydroxycoumarin)

Cat. No.: HY-N0281

Daphnetin (7,8-dihydroxycoumarin), one coumarin derivative isolated from plants of the Genus Daphne, is a **protein kinase** inhibitor, with **IC_{50}s** of 7.67 μM, 9.33 μM and 25.01 μM for EGFR, PKA and PKC in vitro, respectively.



Purity: 99.21%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

DBPR112

Cat. No.: HY-128778

DBPR112 is an orally active furanopyrimidine-based **EGFR** inhibitor with IC_{50}s of 15 nM and 48 nM for $EGFR^{WT}$ and $EGFR^{L858R/T790M}$, respectively. DBPR112 can occupy the ATP-binding site. DBPR112 has significant antitumor efficacy.



Purity: 98.07%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride; Delphinidin 3-O-β-glucoside chloride)

Cat. No.: HY-108052

Delphinidin 3-glucoside chloride (Delphinidin 3-O-glucoside chloride) is an active anthocyanin found in bilberry extract. Delphinidin 3-glucoside chloride induces a pro-apoptotic effect in B cell chronic lymphocytic leukaemia (B CLL).



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Disitamab vedotin (RC48)

Cat. No.: HY-P9985

Disitamab vedotin (RC48) is an antibody-drug conjugate **(ADC)** comprising a monoclonal antibody against human epidermal growth factor receptor 2 **(HER2)** conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity.

Disitamab vedotin

Purity: 97.40%
Clinical Data: Launched
Size: 1 mg, 5 mg

Dosimertinib

Cat. No.: HY-142283

Dosimertinib is a highly potent, selective, and orally efficacious deuterated **EGFR** targeting clinical candidate for the treatment of non-small-cell lung cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DP-C-4

Cat. No.: HY-141481

DP-C-4 is a **Cereblon**-based dual **PROTAC** for simultaneous degradation of **EGFR** and **PARP**.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

EAI045

Cat. No.: HY-100213

EAI045 is an allosteric and the fourth-generation inhibitor of mutant **EGFR** with IC_{50}s of 1.9, 0.019, 0.19 and 0.002 μM for EGFR, $EGFR^{L858R}$, $EGFR^{T790M}$ and $EGFR^{L858R/T790M}$ at 10 μM ATP, respectively.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg, 100 mg

EGFR mutant-IN-1

Cat. No.: HY-125841

EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective $EGFR^{L858R/T790M/C797S}$ mutant inhibitor with an IC_{50} of 27.5 nM, while being a significantly less potent for $EGFR^{WT}$ (IC_{50} >1.0 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR Protein Tyrosine Kinase Substrate

Cat. No.: HY-P2503

EGFR Protein Tyrosine Kinase Substrate is a EGFR protein tyrosine kinase substrate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-1

Cat. No.: HY-19617

EGFR-IN-1 (compound 24) is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-1 hydrochloride

Cat. No.: HY-19617A

EGFR-IN-1 hydrochloride is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 hydrochloride potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-1 TFA

Cat. No.: HY-19617B

EGFR-IN-1 TFA is an orally active and irreversible **L858R/T790M mutant selective EGFR** inhibitor. EGFR-IN-1 TFA potently inhibits Gefitinib-resistant EGFR L858R, T790M with 100-fold selectivity over wild-type EGFR.



Purity: 99.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR-IN-11

Cat. No.: HY-130616

EGFR-IN-11 is a fourth-generation **EGFR**-tyrosine kinase inhibitor (**EGFR-TKI**) with an IC_{50} of 18 nM for triple mutant $EGFR^{L858R/T790M/C797S}$.
EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1.



Purity: 99.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR-IN-12

Cat. No.: HY-17499

EGFR-IN-12 is a 4,6-disubstituted pyrimidine and is a potent, ATP-competitive, irreversible and highly selective **EGFR** inhibitor with an $IC_{50}$of 21 nM. EGFR-IN-12 also inhibits mutant $EGFR^{L858R}$ and $EGFR^{L861Q}$ with IC_{50}s of 63 nM and 4 nM, respectively.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

EGFR-IN-15

Cat. No.: HY-138746

EGFR-IN-15 (compound I-005) is a **EGFR** inhibitor with an IC_{50} of 4 nM. EGFR-IN-15 can be used for oncological diseases research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-16

Cat. No.: HY-137786

EGFR-IN-16 (compound 3) is a potent **EGFR** inhibitor with pIC_{50} of 4.85 and 4.74 for EGFR and HER-2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-17

Cat. No.: HY-115716

EGFR-IN-17 is a potent and selective inhibitor of the **epidermal growth factor receptor** (IC_{50} 0.0002 μM) to overcome C797S-mediated resistance.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-18

Cat. No.: HY-139884

EGFR-IN-18 potently inhibits enzymatic activity in L858R/T790M/C797S mutant **EGFR** (4.9 nM), with a significantly lower activity for wild-type **EGFR** (47 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-2

Cat. No.: HY-100520

EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation **EGFR** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-21

Cat. No.: HY-142678

EGFR-IN-21 is a potent **EGFR** inhibtior with an IC_{50} of 0.38 nM. EGFR-IN-21 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-22

Cat. No.: HY-142679

EGFR-IN-22 is a potent **EGFR** inhibitor with IC_{50}s of 4.91 nM and 0.54 nM for **wild type EGFR** and $EGFR^{L858R/T790M/C797S}$, respectively (CN112538072A, compound 243).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-23

Cat. No.: HY-142680

EGFR-IN-23 is a potent **EGFR** TKI (tyrosine kinase inhibitor) with an IC_{50} of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-24

Cat. No.: HY-142512

EGFR-IN-24, a potent EGFR inhibitor, shows inhibition against EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-25

Cat. No.: HY-142517

EGFR-IN-25 is a potent **EGFR** inhibitor with IC_{50}s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-27

Cat. No.: HY-142519

EGFR-IN-27 is a potent EGFR inhibitor with IC_{50}s of <50 nM for EGFR Del, L858R, Del/T790M, L858R/T790M, Del/T790M/C797S, and L858R/T790M/C797S, respectively (WO2021249324A1, compound 511).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-28

Cat. No.: HY-142681

EGFR-IN-28 is a potent EGFR inhibitor. EGFR-IN-28 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-29

Cat. No.: HY-143729

EGFR-IN-29 is a potent **EGFR** inhibitor, example J-022, extracted from Patent WO2021160087.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-30

Cat. No.: HY-144044

EGFR-IN-30 is a potent **EGFR** inhibitor with IC_{50}s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-31

Cat. No.: HY-144048

EGFR-IN-31 is a potent inhibitor of **EGFR**. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-32

Cat. No.: HY-144049

EGFR-IN-32 is a potent inhibitor of **EGFR**. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-33

Cat. No.: HY-144050

EGFR-IN-33 is a potent inhibitor of **EGFR**. EGFR-IN-33 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-34

Cat. No.: HY-144051

EGFR-IN-34 is a potent inhibitor of **EGFR**. EGFR-IN-34 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-35

Cat. No.: HY-144052

EGFR-IN-35 is a potent inhibitor of **EGFR**. EGFR-IN-35 is an anti-tumor drug with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-36

Cat. No.: HY-144053

EGFR-IN-36 is a potent **EGFR** inhibitor with IC_{50}s of 19.09 nM, 120.01 nM, 2.35 nM for EGFR (WT), HER2 (WT), HER2 (A775_G776insYVMA), respectively. EGFR-IN-36 has potential for wild and/or mutant EGFR and/or HER2 kinase mediated tumors research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-37

Cat. No.: HY-144054

EGFR-IN-37 is a potent inhibitor of **EGFR**. EGFR-IN-37 is an anti-tumor drug with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-38

Cat. No.: HY-144055

EGFR-IN-38 is a potent inhibitor of **EGFR**. EGFR-IN-38 is an anti-tumor drug with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-39

Cat. No.: HY-144056

EGFR-IN-39 is a potent inhibitor of **EGFR**. EGFR-IN-39 is an anti-tumor drug with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-40

Cat. No.: HY-143901

EGFR-IN-40 (compound 3z) is a potent **BTK**, **EGFR**, and **ITK** inhibitor with IC_{50} values of 1.2 nM, 5.3 nM, and 46.1 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-42

Cat. No.: HY-145823

EGFR-IN-42 (Compound 17b) is a potent inhibitor of **EGFR** with single-digit nanomolar activity. EGFR-IN-42 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-42 retains both ER antagonist activity and EGFR inhibition.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-43

Cat. No.: HY-145824

EGFR-IN-43 (Compound 17c) is a potent inhibitor of **EGFR** with single-digit nanomolar activity. EGFR-IN-43 connects tamoxifen or endoxifen with the EGFR-inhibitor gefitinib via a covalent linkage. EGFR-IN-43 retains both ER antagonist activity and EGFR inhibition.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-44

Cat. No.: HY-145844

EGFR-IN-44 (Compound 6a) is a potent, orally active **EGFR** tyrosine kinase inhibitor with an IC_{50} of 4.11 nM. EGFR-IN-44 induces cell **apoptosis** and shows an oral bioavailability value of 33.57%. EGFR-IN-44 can be studied for non-small-cell lung cancers.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-45

Cat. No.: HY-145867

EGFR-IN-45 is a potent epidermal growth factor receptor (**EGFR**) pan inhibitor, with IC_{50}s of 0.4 μM and 1.6 μM for **EGFR** and **CDK2**, respectively. EGFR-IN-45 also inhibit Topo I and Topo II. EGFR-IN-45 arrests cancer cells in the pre-G1 phase and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-46

Cat. No.: HY-144794

EGFR-IN-46 is a potent **EGFR** and **FAK** dual inhibitor with IC_{50}s of 20.17 nM, 14.25 nM, respectively. EGFR-IN-46 significantly inhibits the growth of cancer cells. EGFR-IN-46 induces cell **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-47

Cat. No.: HY-143337

EGFR-IN-47 is a potent and orally active $EGFR^{L858R/T790M/C797S}$ inhibitor with an IC_{50} of 0.01 μM. EGFR-IN-47 induces cell cycle attest and cell **apoptosis**. EGFR-IN-47 has the potential for the research of NSCLC.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-48

Cat. No.: HY-143445

EGFR-IN-48 is a potent and orally active **EGFR** inhibitor with IC_{50}s of 0.193 nM, 0.251 nM, 10.4 nM for $EGFR^{d19/TM/CS}$, $EGFR^{LR/TM/CS}$, $EGFR^{WT}$, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-49

Cat. No.: HY-146782

EGFR-IN-49 is a potent and selective **EGFR** inhibitor with IC_{50}s of 65.0 nM and 13.6 nM for $EGFR^{T790M}$ and $EGFR^{T790M/L858R}$, respectively. EGFR-IN-49 induces late **apoptosis** in a dose-dependent manner.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-5

Cat. No.: HY-111415

EGFR-IN-5 is a **EGFR** inhibitor with IC_{50}s of 10.4, 1.1, 34, 7.2 nM for EGFR, $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, and $EGFR^{L858R/T790M/C797S}$, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR-IN-51

Cat. No.: HY-146471

EGFR-IN-51 (Compound 6) is a potent **EGFR** inhibitor with IC_{50} values of 0.493, 102.60 and 461.63 μM against EGFR, **EGFR L858R-TK** and **EGFR T790M-TK**, respectively. EGFR-IN-51 shows cytotoxic activity against cancer cell lines and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-52

Cat. No.: HY-146472

EGFR-IN-52 (Compound 4) is a potent **EGFR** inhibitor with IC_{50} values of 0.358, 86.02 and 432.67 μM against EGFR, **EGFR L858R-TK** and **EGFR T790M-TK**, respectively. EGFR-IN-52 shows cytotoxic activity against cancer cell lines and induces **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-53

Cat. No.: HY-146473

EGFR-IN-53 (Compound 7) is a potent **EGFR** inhibitor with an IC_{50} of 8.264 μM. EGFR-IN-53 shows cytotoxic activity against cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-54

Cat. No.: HY-146474

EGFR-IN-54 (Compound 3c) is a potent **EGFR** inhibitor with an IC_{50} of 1.623 μM. EGFR-IN-54 shows cytotoxic activity against cancer cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-55

Cat. No.: HY-146132

EGFR-IN-55 (Compound 8a) is a potent **EGFR** inhibitor with IC_{50} values of 70 nM and 3.9 nM against $EGFR^{WT}$ and $EGFR^{L858R/T790M}$, respectively. EGFR-IN-55 arrests NCI-H1975 cells in G0/G1 phase and shows anticancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-56

Cat. No.: HY-146136

EGFR-IN-56 (Compound 13a) is a potent **EGFR** inhibitor with IC_{50} values of 541.7 nM and 132.1 nM against $EGFR^{T790M}$ and $EGFR^{T790M/L858R}$, respectively. EGFR-IN-56 blocks cancer cells in G2/M phase and induce into late **apoptosis**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-57

Cat. No.: HY-146138

EGFR-IN-57 (Compound 25a) is a potent, orally active **EGFR-TK** inhibitor with an IC_{50} of 0.054 μM. EGFR-IN-57 also inhibits **VEGFR-2**, **CK2α**, **topoisomerase IIβ** and **tubulin polymerization** with IC_{50} values of 0.087, 0.171, 0.13 and 3.61 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR-IN-7

Cat. No.: HY-128862

EGFR-IN-7 (compound 34) is a selective and potent **EGFR kinase** inhibitor extracted from patent WO2019015655A1, has IC_{50}s of 7.92 nM and 0.218 nM for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) respectively, and shows anti-tumor activity.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

EGFR-IN-8

Cat. No.: HY-126320

EGFR-IN-8 is a dual **EGFR** and **c-Met** inhibitor, compound 48. EGFR-IN-8 can be a promising candidate for further development to target EGFR TKI-resistant NSCLC.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EGFR-IN-9

Cat. No.: HY-18213

EGFR-IN-9 (Compound 8) is a potent **EGFR kinase** inhibitor with IC_{50}s of 7 nM, 28 nM for the wild type EGFR kinase and double mutant EGFR kinase (L858R/T790M). EGFR-IN-9 has antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/BRAF-IN-1

Cat. No.: HY-115933

EGFR/BRAF-IN-1 (compound 21), a 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivative, is a potent **EGFR/BRAF** inhibitor with an IC_{50} of 45 nM for $BRAF^{V600E}$. EGFR/BRAF-IN-1 inhibits cancer cell proliferation (GI_{50}=35 nM). EGFR/BRAF-IN-1 shows good antioxidant activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/CSC-IN-1

Cat. No.: HY-132883

EGFR/CSC-IN-1 is a potential **EGFR** (IC_{50} 10.52 nM) and cancer stem cell (CSC) dual inhibitor for triple-negative breast cancer treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/ErbB-2/ErbB-4 inhibitor-2

Cat. No.: HY-112420

EGFR/ErbB-2/ErbB-4 inhibitor-2 (Compound 5) is a **EGFR** and **ErbB** inhibitor with IC_{50}s of 0.017 μM, 0.08 μM, 1.91 μM.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EGFR/HER2-IN-2

Cat. No.: HY-115951

EGFR/HER2-IN-2 (Compound ZINC35560729) is a dual inhibitor of **EGFR** and **HER2** with IC_{50} values of 5.02 μM and 0.83 μM against EGFR and HER2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EGFR/HER2-IN-3

Cat. No.: HY-115952

EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual inhibitor of **EGFR** and **HER2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EMI1

Cat. No.: HY-138072

EMI1 is an **EGFR ex19del/T790M/C797S** and **EGFR L858R/T790M/C797S** inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

EMI48

Cat. No.: HY-131066

EMI48, the derivative of EMI1, displays greater potency toward mutant **EGFR** than EMI1. EMI48 inhibits **EGFR** triple mutants.



Purity: 99.02%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

EMI56

Cat. No.: HY-131067

EMI56, the derivative of EMI1, displays greater potency toward mutant **EGFR** than EMI1. EMI56 inhibits **EGFR** triple mutants.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Epertinib

(S-22611)

Cat. No.: HY-107367

Epertinib (S-22611) is a potent, oral, reversible, and selective tyrosine kinase inhibitor of **EGFR**, **HER2** and **HER4**, with IC_{50}s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib shows potent antitumor activity.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 1 mg

Epertinib hydrochloride

(S-22611 hydrochloride)

Cat. No.: HY-107367A

Epertinib hydrochloride (S-22611 hydrochloride) is a potent, orally active, reversible, and selective tyrosine kinase inhibitor of **EGFR**, **HER2** and **HER4**, with IC_{50}s of 1.48 nM, 7.15 nM and 2.49 nM, respectively. Epertinib hydrochloride shows potent antitumor activity.



Purity: 99.76%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Epitinib

(HMPL-813)

Cat. No.: HY-139300

Epitinib is an orally active and selective **epidermal growth factor receptor tyrosine kinase** inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib can be used for the research of cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Epitinib succinate

(HMPL-813 succinate)

Cat. No.: HY-139300A

Epitinib succinate is an orally active and selective **epidermal growth factor receptor tyrosine kinase** inhibitor (EGFR-TKI) designed for optimal brain penetration. Epitinib succinate can be used for the research of cancer.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Erlotinib

(CP-358774; NSC 718781; OSI-774)

Cat. No.: HY-50896

Erlotinib (CP-358774) is a directly acting **EGFR** tyrosine kinase inhibitor, with an IC_{50} of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC_{50} of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Erlotinib Hydrochloride (CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride)

Cat. No.: HY-12008

Erlotinib Hydrochloride (CP-358774 Hydrochloride) inhibits purified **EGFR** kinase with an IC_{50} of 2 nM.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Erlotinib mesylate (CP-358774 mesylate; NSC 718781 mesylate; OSI-774 mesylate)

Cat. No.: HY-12008A

Erlotinib mesylate (CP-358774 mesylate) inhibits purified **EGFR** kinase with an IC_{50} of 2 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Erlotinib-13C6

(CP-358774-13C6; NSC 718781-13C6; OSI-774-13C6) **Cat. No.:** HY-50896S1

Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC_{50} of 2 nM for human EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

Erlotinib-d6

(CP-358774-d6; NSC 718781-d6; OSI-774-d6) **Cat. No.:** HY-50896S

Erlotinib D6 (CP-358774 D6) is a deuterium labeled Erlotinib (CP-358774). Erlotinib is a directly acting inhibitor EGFR tyrosine kinase inhibitor with an IC_{50} of 2 nM for human EGFR.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Erlotinib-d6 hydrochloride (CP-358774-d6 hydrochloride; NSC 718781-d6 hydrochloride; OSI-774-d6 hydrochloride)

Cat. No.: HY-12008S

Erlotinib D6 hydrochloride (CP-358774 D6 hydrochloride) a deuterium labeled Erlotinib Hydrochloride. Erlotinib Hydrochloride inhibits purified EGFR kinase with an IC_{50} of 2 nM.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 1 mg

Falnidamol

(BIBX 1382) **Cat. No.:** HY-10322

Falnidamol (BIBX 1382) is an orally active, selective **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC_{50}=3.4 μM) and a range of other related tyrosine kinases (IC_{50}>10 μM).



Purity: 97.03%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

FIIN-3

Cat. No.: HY-18603

FIIN-3 is an irreversible inhibitor of **FGFR** with an **IC_{50}** of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Gefitinib

(ZD1839) **Cat. No.:** HY-50895

Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC_{50} of 54 nM) and that blocks EGF-stimulated **EGFR** autophosphorylation in tumor cells.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Gefitinib hydrochloride

(ZD-1839 hydrochloride) **Cat. No.:** HY-50895A

Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 33 nM.



Purity: 99.85%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg, 1 g, 5 g

Gefitinib N-oxide

Cat. No.: HY-100636

Gefitinib N-oxide is the N-oxide derivative of Gefitinib. Gefitinib is an **EGFR tyrosine kinase** inhibitor, with **IC_{50}** of 2-37 nM in NR6wtEGFR cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gefitinib-based PROTAC 3

Cat. No.: HY-123921

Gefitinib-based PROTAC 3, conjugating an **EGFR** binding element to a **von Hippel-Lindau** ligand via a linker, induces **EGFR** degradation with **DC_{50}**s of 11.7 nM and 22.3 nM in HCC827(exon 19 del) and H3255 (L858R mutantion) cells, respectively.



Purity: 99.98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Gefitinib-d3

Cat. No.: HY-50895S2

Gefitinib-d3 (ZD1839-d3) is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 33 nM.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Gefitinib-d6

(ZD1839-d6) Cat. No.: HY-50895S1

Gefitinib-d6 (ZD1839-d6) is the deuterium labeled Gefitinib. Gefitinib (ZD1839) is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor with an **IC_{50}** of 33 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gefitinib-d8

(ZD1839-d8) Cat. No.: HY-50895S

Gefitinib D8 (ZD1839 D8) is a deuterium labeled Gefitinib. Gefitinib is an **EGFR tyrosine kinase** inhibitor, with **IC_{50}** of 2-37 nM in NR6wtEGFR cells.



Purity: 98.42%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Genistein

(NPI 031L) Cat. No.: HY-14596

Genistein, a soy isoflavone, is a multiple **tyrosine kinases** (e.g., **EGFR**) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering **apoptosis**, the cell cycle, and angiogenesis and inhibiting metastasis.



Purity: 99.84%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 100 mg, 500 mg

Genistein-d4

(NPI 031L-d4) Cat. No.: HY-14596S

Genistein-d4 (NPI 031L-d4) is the deuterium labeled Genistein. Genistein, a soy isoflavone, is a multiple **tyrosine kinases** (e.g.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HER2-IN-5

Cat. No.: HY-143733

HER2-IN-5 is a potent and orally active **HER-2** inhibitor, example 10, extracted from patent WO2021164697.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HER2-IN-7

Cat. No.: HY-143874

HER2-IN-7 is a potent inhibitor of **HER2**. Deregulation of ErbB family signalling modulates proliferation, invasion, metastasis, angiogenesis, and tumour cell survival.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HER2-IN-8

Cat. No.: HY-144097

HER2-IN-8 is a **HER-2** inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HKI-357

Cat. No.: HY-103443

HKI-357 is an irreversible dual inhibitor of **EGFR** and **ERBB2** with **IC_{50}**s of 34 nM and 33 nM, respectively. HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.



Purity: 99.65%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Icotinib

(BPI-2009) Cat. No.: HY-15164A

Icotinib (BPI-2009) is a potent and specific **EGFR** inhibitor with an **IC_{50}** of 5 nM; also inhibits mutant $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{T790M}$ and $EGFR^{L861Q}$.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Icotinib Hydrochloride

(BPI-2009H) Cat. No.: HY-15164

Icotinib Hydrochloride (BPI-2009) is a potent and specific **EGFR** inhibitor with an **IC_{50}** of 5 nM; also inhibits mutant $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{T790M}$ and $EGFR^{L861Q}$.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JBJ-02-112-05

Cat. No.: HY-135914

JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active **EGFR** inhibitor with an IC_{50} of 15 nM for $EGFR^{L858R/T790M}$.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JBJ-04-125-02

Cat. No.: HY-135805

JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active **EGFR** inhibitor with an IC_{50} of 0.26 nM for $EGFR^{L858R/T790M}$. JBJ-04-125-02 can inhibit cancer cell proliferation and $EGFR^{L858R/T790M/C797S}$ signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

JCN037

(JGK037)

Cat. No.: HY-136430

JCN037 (JGK037) is non-covalent and BBB-penetrant **EGFR** tyrosine kinase inhibitor, with IC_{50} values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRv, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JND3229

Cat. No.: HY-119944

JND3229 is a highly potent and fourth-generation $EGFR^{C797S}$ reversible inhibitor with IC_{50} value of 5.8 nM, and also potently suppressed $EGFR^{L858R/T790M}$ and $EGFR^{WT}$ with IC_{50} values of 30.5 and 6.8 nM.



Purity: 99.38%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JNJ28871063 hydrochloride

Cat. No.: HY-103441

JNJ28871063 hydrochloride is an orally active, highly selective and ATP competitive **pan-ErbB kinase** inhibitor with IC_{50} values of 22 nM, 38 nM, and 21 nM for ErbB1, ErbB2, and ErbB4, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Khellin

Cat. No.: HY-B1394

Khellin is a furochromone that can be isolated from Ammi visnuga L.. Khellin is an **EGFR** inhibitor with an IC_{50} of 0.15 μM. Khelline has anti-proliferative activity in vitro. Khellin has antispasmodic and coronary vasodilator effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib

(GW572016; GW2016)

Cat. No.: HY-50898

Lapatinib (GW572016) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: 99.83%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Lapatinib ditosylate (GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate)

Cat. No.: HY-50898B

Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Lapatinib ditosylate

(GW572016 ditosylate; GW2016 ditosylate)

Cat. No.: HY-50898A

Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg, 1 g

Lapatinib-d4-1

(GW572016-d4-1; GW2016-d4-1)

Cat. No.: HY-50898S3

Lapatinib-d4-1 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib-d5

(GW572016-d5; GW2016-d5) Cat. No.: HY-50898S2

Lapatinib-d5 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib-d7 dihydrochloride

(GW572016-d7 dihydrochloride; GW2016-d7 dihydrochloride) Cat. No.: HY-50898S1

Lapatinib-d7 (GW572016-d7) dihydrochloride is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lapatinib-d7 ditosylate

Cat. No.: HY-50898BS

Lapatinib-d7 (GW572016-d7) ditosylate is the deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the **ErbB-2** and **EGFR** tyrosine kinase domains with IC_{50} values against purified **EGFR** and **ErbB-2** of 10.2 and 9.8 nM, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Lavendustin A

(RG-14355) Cat. No.: HY-18963

Lavendustin A (RG-14355), isolated from Streptomyces Griseolavendus, is a potent, specific and ATP-competitive inhibitor of **tyrosine kinase**, with an IC_{50} of 11 ng/mL for EGFR-associated tyrosine kinase.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Lavendustin C

Cat. No.: HY-W013857

Lavendustin C is a potent **Ca^{2+} calmodulin-dependent kinase II (CaMK II)** inhibitor with an IC_{50} of 0.2 μM. Lavendustin C inhibits **EGFR**-associated tyrosine kinase (IC_{50}=0.012 μM) and **pp60$^{c\text{-}src(+)}$** kinase (IC_{50}=0.5 μM) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lazertinib

(YH25448; GNS-1480) Cat. No.: HY-109061

Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation **EGFR** tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer.



Purity: 99.73%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LDC0496

Cat. No.: HY-146262

LDC0496 is a potent and selective **EGFR** inhibitor. LDC0496 possesses intense inhibitory potency toward EGFR and Her2 exon20 insertion mutations, as well as selectivity over wild type EGFR and within the kinome.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lifirafenib

(BGB-283) Cat. No.: HY-18957

Lifirafenib (BGB-283) is a novel and potent **Raf** Kinase and **EGFR** inhibitor with IC_{50} values of 23 and 29 nM for recombinant $BRaf^{V600E}$ and EGFR, respectively.



Purity: 98.02%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mal-amido-PEG8-Val-Ala-PAB-SG3200

Cat. No.: HY-139957

Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a site-specific **antibody-drug conjugate** that binds **HER2** (extracted from patent WO2016166300A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Margetuximab

Cat. No.: HY-P99030

Margetuximab (MGAH22) is a chimeric anti-**HER2** monoclonal antibody optimized Fc domain, with an EC_{50} value of 39.33 ng/mL. Margetuximab can be used for researching metastatic HER2-positive breast cancer.

Margetuximab

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mavelertinib

(PF-06747775)

Cat. No.: HY-12972

Mavelertinib is a selective, orally available and irreversible **EGFR tyrosine kinase inhibitor (EGFR TKI)**, with IC_{50}s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively.



Purity: 99.21%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MC-Val-Cit-PAB-Amide-TLR7 agonist 4

Cat. No.: HY-145960

MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a **HER2-TLR7** and **HER2-TLR8** immune agonist conjugate.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Methyl 2,5-dihydroxycinnamate

Cat. No.: HY-101006

Methyl 2,5-dihydroxycinnamate is an erbstatin analog and a stable, potent inhibitor of EGFR kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mobocertinib

(TAK-788; AP32788)

Cat. No.: HY-135815

Mobocertinib (TAK-788) is a potent and orally active inhibitor of **EGFR** and **HER2** oncogenic mutants, including exon 20 insertions, with selectivity over WT EGFR. Antitumor activity.



Purity: 99.60%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

Mobocertinib succinate

(TAK-788 succinate; AP32788 succinate)

Cat. No.: HY-135815A

Mobocertinib succinate (TAK-788 succinate) is a potent and orally active inhibitor of **EGFR** and **HER2** oncogenic mutants, including exon 20 insertions, with selectivity over WT EGFR. Antitumor activity.



Purity: 99.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 500 mg

MTX-211

Cat. No.: HY-107364

MTX-211 is a dual inhibitor of **EGFR** and **PI3K**, used for the treatment of cancer and other diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Mubritinib

(TAK-165)

Cat. No.: HY-13501

Mubritinib (TAK-165) is a potent and selective **EGFR2/HER2** inhibitor with an IC_{50} of 6 nM.



Purity: 99.91%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Mutant EGFR inhibitor

Cat. No.: HY-13984

Mutant EGFR inhibitor is a potent and selective mutant **EGFR** inhibitor extracted from patent WO 2013014448 A1; inhibits $EGFR^{L858R}$, $EGFR^{Exon\ 19\ deletion}$ and $EGFR^{T790M}$.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Mutated EGFR-IN-1

(Osimertinib analog)

Cat. No.: HY-78869

Mutated EGFR-IN-1 (Osimertinib analog) is a useful intermediate for the inhibitors design for mutated **EGFR**, such as L858R EGFR, ExonI9 deletion activating mutant and T790M resistance mutant.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Mutated EGFR-IN-2

Cat. No.: HY-128860

Mutated EGFR-IN-2 (compound 91) is a mutant-selective **EGFR** inhibitor extracted from patent WO2017036263A1, which potently inhibits single-mutant EGFR (T790M) and double-mutant EGFR (including L858R/T790M (IC_{50}=1nM) and ex19del/T790M), and can suppress activity...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mutated EGFR-IN-3

Cat. No.: HY-130608

Mutated EGFR-IN-3 (compound 3) is a potent, ATP-competitive and highly selective allosteric dibenzodiazepinone inhibitor of the **EGFR(L858R/T790M)** and **EGFR(L858R/T790M/C797S)** mutants with IC_{50} values of 12 nM and 13 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Naquotinib

(ASP8273)

Cat. No.: HY-19729

Naquotinib (ASP8273) is an orally available, mutant-selective and irreversible **EGFR** inhibitor; with IC_{50}s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Naquotinib mesylate

(ASP8273 (mesylate))

Cat. No.: HY-19803

Naquotinib mesylate (ASP8273 mesylate) is an orally available, mutant-selective and irreversible **EGFR** inhibitor; with IC_{50}s of 8-33 nM toward EGFR mutants and 230 nM for EGFR.



Purity: 98.02%
Clinical Data: Phase 3
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nazartinib

(EGF816)

Cat. No.: HY-12872

Nazartinib (EGF816) is a covalent mutant-selective **EGFR** inhibitor, with K_i and K_{inact} of 31 nM and 0.222 min^{-1} on EGFR(L858R/790M) mutant, respectively.



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nazartinib mesylate

(EGF816 mesylate)

Cat. No.: HY-12872A

Nazartinib mesylate (EGF816 mesylate) is a novel, covalent mutant-selective **EGFR** inhibitor, with K_i and K_{inact} of 31 nM and 0.222 min^{-1} on EGFR(L858R/790M) mutant, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Neratinib

(HKI-272)

Cat. No.: HY-32721

Neratinib (HKI-272) is an orally available, irreversible **tyrosine kinase** inhibitor with IC_{50}s of 59 nM and 92 nM for HER2 and EGFR, respectively.



Purity: 99.59%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Neratinib-d6

Cat. No.: HY-32721S

Neratinib-d6 (HKI-272-d6) is the deuterium labeled Neratinib. Neratinib (HKI-272) is an orally available, irreversible **tyrosine kinase** inhibitor with IC_{50}s of 59 nM and 92 nM for HER2 and EGFR, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Nimotuzumab

Cat. No.: HY-P9968

Nimotuzumab is a humanized IgG1 monoclonal antibody targeting **EGFR** with a K_D of 0.21 nM. Nimotuzumab is directed against the extracellular domain of the EGFR blocking the binding to its ligands.

Nimotuzumab

Purity: 96.30%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NRC-2694

Cat. No.: HY-19909

NRC-2694 is an epidermal growth factor receptor (**EGFR**) antagonist with anti-cancer and anti-proliferative properties.



Purity: 99.71%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 20 mg

NSC 228155

Cat. No.: HY-101084

NSC 228155 is an activator of **EGFR**, binds to the extracellular region of **EGFR** and enhance tyrosine phosphorylation of EGFR.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NSC114126

Cat. No.: HY-144445

NSC114126 is a potent and orally active inhibitor of EGFR tyrosine kinase (**EGFR-TK**). NSC114126 has strong antiproliferative activities. NSC114126 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC381467

Cat. No.: HY-144444

NSC381467 is a potent and orally active inhibitor of EGFR tyrosine kinase (**EGFR-TK**). NSC381467 has strong antiproliferative activities. NSC381467 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC81111

Cat. No.: HY-144441

NSC81111 is a potent and orally active **EGFR-TK** inhibitor with an IC_{50} of 0.15 nM. NSC81111 has anticaner effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-Desmethyl gefitinib

Cat. No.: HY-100064

O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity. O-desmethyl gefitinib inhibits **EGFR** with an IC_{50} of 36 nM in subcellular assays.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-Desmethyl gefitinib D8

Cat. No.: HY-100064S

O-Desmethyl gefitinib D8 is a deuterium labeled O-Desmethyl gefitinib. O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

O-Desmethyl gefitinib-d6

Cat. No.: HY-100064S1

O-Desmethyl Gefitinib-d6 is the deuterium labeled O-Desmethyl gefitinib. O-Desmethyl gefitinib is an active metabolite of Gefitinib in human plasma. The formation of O-desmethyl gefitinib is dependent on CYP2D6 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Olafertinib

Cat. No.: HY-19815

Olafertinib is a third-generation **EGFR** TKI, with GI_{50} values of 5 nM (EGFR L858R/T790M), 10 nM (EGFR del19) and 689 nM (EGFR WT), respectively. Olafertinib has the potential for NSCLC research.



Purity: 99.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Olmutinib

(HM61713, BI 1482694)

Cat. No.: HY-19730

Olmutinib (HM61713; BI-1482694) is an orally active and irreversible third **EGFR tyrosine kinase** inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib is used for NSCLC.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Oritinib

(SH-1028)

Cat. No.: HY-139920

Oritinib (SH-1028), an irreversible third-generation **EGFR TKI**, overcomes T790M-mediated resistance in non-small cell lung cancer.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oritinib mesylate

(SH-1028 mesylate)

Cat. No.: HY-139920A

Oritinib (SH-1028) mesylate is a selective, orally active, and pyrimidine-based irreversible inhibitor of **EGFR** with an IC_{50} of 18 nM. Oritinib (SH-1028) mesylate exhibits potent activity against EGFR sensitive and resistant (T790 M) mutations.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Osimertinib

(AZD-9291; Mereletinib) Cat. No.: HY-15772

Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective **EGFR** inhibitor with an apparent IC_{50} of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.



Purity: 99.92%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Osimertinib dimesylate

(AZD-9291 dimesylate; Mereletinib dimesylate) Cat. No.: HY-79077

Osimertinib dimesylate (AZD-9291 dimesylate) is an irreversible and mutant selective **EGFR** inhibitor with IC_{50}s of 12 and 1 nM against $EGFR^{L858R}$ and $EGFR^{L858R/T790M}$, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Osimertinib mesylate

(AZD-9291 mesylate; Mereletinib mesylate) Cat. No.: HY-15772A

Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective **EGFR** inhibitor with an apparent IC_{50} of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Osimertinib-d6

(AZD-9291-d6; Mereletinib-d6) Cat. No.: HY-15772S

Osimertinib D6 (AZD-9291 D6) is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective **EGFR** inhibitor with an apparent IC_{50} of 12 nM against L858R and 1 nM against L858R/T790M.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 1 mg

pan-HER-IN-1

Cat. No.: HY-144676

pan-HER-IN-1 (Compound C5) is an irreversible, orally active pan-**HER** inhibitor with IC_{50} values of 0.38, 1.6, 2.2 and 3.5 nM against **EGFR**, **HER4**, $EGFR^{T790M/L858R}$ and **HER2**, respectively. pan-HER-IN-1 induces **apoptosis** and shows antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

pan-HER-IN-2

Cat. No.: HY-144677

pan-HER-IN-2 (Compound C6) is a reversible, orally active pan-**HER** inhibitor with IC_{50} values of 0.72, 2.0, 8.2 and 75.1 nM against **EGFR**, **HER4**, $EGFR^{T790M/L858R}$ and **HER2**, respectively. pan-HER-IN-2 induces **apoptosis** and shows antitumor activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Panitumumab

(ABX-EGF) Cat. No.: HY-P99041

Panitumumab (ABX-EGF) is a fully human IgG2 anti-**EGFR** monoclonal antibody. Panitumumab has an anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD 174265

Cat. No.: HY-112411

PD 174265 is a potent, cell-permeable, reversible, and selective inhibitor of **EGFR** with an IC_{50} of 450 pM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PD-089828

Cat. No.: HY-112345

PD-089828 is an ATP competitive inhibitor of **FGFR-1**, **PDGFR-β** and **EGFR** (IC_{50}s=0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of **c-Src** tyrosine kinase (IC_{50}=0.18 μM). PD-089828 also inhibits **MAPK** with an IC_{50} of 7.1 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD-161570

Cat. No.: HY-100434

PD-161570 is a potent and ATP-competitive **human FGF-1 receptor** inhibitor with an IC_{50} of 39.9 nM and a K_i of 42 nM. PD-161570 also inhibits the **PDGFR**, **EGFR** and **c-Src tyrosine kinases** with IC_{50} values of 310 nM, 240 nM, and 44 nM, respectively.



Purity: 99.04%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

PD153035

(SU-5271; AG1517; ZM 252868) Cat. No.: HY-14346

PD153035 (SU-5271; AG1517; ZM 252868) is a potent **EGFR** inhibitor with K_i and IC_{50} of 6 and 25 pM, respectively.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PD153035 Hydrochloride (SU-5271 Hydrochloride; AG1517 Hydrochloride; ZM 252868 Hydrochloride)

Cat. No.: HY-12013

PD153035 Hydrochloride (SU-5271 Hydrochloride) is a potent **EGFR** inhibitor with K_i and IC_{50} of 6 and 25 pM, respectively.



Purity: 99.06%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PD158780

Cat. No.: HY-18609

PD158780 is a potent **EGFR** family inhibitor with IC_{50}s of 8 pM, 49, 52, 52 nM for EGFR, ErbB2, ErbB3, and ErbB4, respectively.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg

PD168393

Cat. No.: HY-13896

PD168393 is a potent, selective and cell-permeable inhibitor of **EGFR tyrosine kinase** and **ErbB2**. PD168393 irreversiblely inactivates EGF receptor (IC_{50}=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

PDZ1i

(113B7) Cat. No.: HY-124813

PDZ1i is a potent, BBB-penetrated and specific **MDA-9/Syntenin** inhibitor. PDZ1i inhibits crucial GBM (glioblastoma multiforme) signaling involving **FAK** and **EGFRvIII**. PDZ1i reduces **MMP** secretion. PDZ1i can improve survival of brain tumor-bearing mice and reduce tumor invasion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pelitinib

(EKB-569; WAY-EKB 569) Cat. No.: HY-32718

Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: 98.80%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Pelitinib-d6

Cat. No.: HY-32718S

Pelitinib-d6 (EKB-569-d6) is the deuterium labeled Pelitinib. Pelitinib (EKB-569) is an irreversible inhibitor of **EGFR** with an IC_{50} of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC_{50}s of 282, 800, and 1255 nM, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

Pertuzumab

Cat. No.: HY-P9912

Pertuzumab, a humanized IgG1 monoclonal antibody, is a **HER2** dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.

Purity: 99.10%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Pertuzumab (PBS)

Cat. No.: HY-P9912A

Pertuzumab (PBS), a humanized monoclonal antibody, is a **HER2** dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-06459988

Cat. No.: HY-19985

PF-06459988 is an irreversible inhibitor of T790M-Containing EGFR Mutants.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF-6274484

Cat. No.: HY-101450

PF-6274484 is a potent **EGFR** inhibitor with K_is of 0.14 nM and 0.18 nM for EGFR-L858R/T790M and WT EGFR, respectively. PF-6274484 inhibits EGFR-L858R/T790M autophosphorylation in H1975 tumor cells and EGFR WT in A549 tumor cells with IC_{50}s of 6.6 and 5.8 nM, respectively.



Purity: 98.41%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PKI-166

Cat. No.: HY-117155

PKI-166 is a potent, selective and orally bioavailable **EGFR tyrosine kinase** inhibitor, with an IC_{50} of 0.7 nM.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

PKI-166 hydrochloride

Cat. No.: HY-110328

PKI-166 hydrochloride is a potent, selective and orally active **EGFR tyrosine kinase** inhibitor, with an IC_{50} of 0.7 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated

Cat. No.: HY-P2548

pp60 (v-SRC) Autophosphorylation Site, Phosphorylated is the phosphorylated peptide of an EGFR substrate. pp60 (v-SRC) Autophosphorylation Site, Phosphorylated can be used for the screening of EGFR Kinase inhibitors via phosphorylated-substrate quantification.

RRLIEDNE-{pTyr}-TARG

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC EGFR degrader 2

Cat. No.: HY-144304

PROTAC EGFR degrader 2 is a potent PROTAC **EGFR** degrader. PROTAC EGFR degrader 2 exhibits excellent antiproliferative activity with IC_{50} of 4.0 nM and good EGFR degradation activity with DC50 of 36.51 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PROTAC EGFR degrader 3

Cat. No.: HY-144605

PROTAC EGFR degrader 3 is a potent **PROTAC EGFR** degrader. PROTAC EGFR degrader 3 shows excellent cellular activity against the H1975 and HCC827 cells with high selectively. PROTAC EGFR degrader 3 shows that the lysosome is involved in the degradation process of EGFR mutant degradation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pyrotinib

(SHR-1258)

Cat. No.: HY-104065

Pyrotinib (SHR-1258) is a potent and selective **EGFR/HER2** dual inhibitor with IC_{50}s of 13 and 38 nM, respectively.



Purity: 99.61%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Pyrotinib dimaleate

(SHR-1258 dimaleate)

Cat. No.: HY-104065B

Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective **EGFR/HER2** dual inhibitor with IC_{50}s of 13 and 38 nM, respectively.



Purity: 99.63%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg

Rezivertinib

(BPI-7711)

Cat. No.: HY-109189

Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI). Rezivertinib exhibits high potency against the common activation EGFR and the resistance T790M mutations.



Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RG13022

(Tyrphostin RG13022)

Cat. No.: HY-101429

RG13022 is a **tyrosine kinase** inhibitor; inhibits the autophosphorylation reaction of the EGF receptor with an IC_{50} of 4 μM.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RG14620

(Tyrphostin RG14620) Cat. No.: HY-101426

RG14620 is an **EGFR** inhibitor with an IC_{50} of 3 μM.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rociletinib

(CO-1686; AVL-301; CNX-419) Cat. No.: HY-15729

Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of **EGFR** including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rociletinib hydrobromide (CO-1686 hydrobromide; AVL-301 hydrobromide; CNX-419 hydrobromide)

Cat. No.: HY-15729A

Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of **EGFR** including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.



Purity: 98.04%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RTC-5

(TRC-382) Cat. No.: HY-123952

RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an **EGFR** driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sapitinib

(AZD-8931) Cat. No.: HY-13050

Sapitinib (AZD-8931) is a reversible, ATP competitive **EGFR** inhibitor of with IC_{50}s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SC209

Cat. No.: HY-144880

SC209, an **ADC cytotoxin** extracted from patent WO2021247798, is used in synthesis of anti-**EGFR** antibody-drug conjugate ADC. SC209 is a metabolite of STRO-002.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Selatinib

Cat. No.: HY-116437

Selatinib is a reversible and orally active dual **EGFR** and **ErbB2** inhibitor with IC_{50}s of 13 nM and 22.5 nM, respectively. Selatinib has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Simotinib

Cat. No.: HY-101820

Simotinib is a selective, specific, and orally bioavailable **EGFR** tyrosine kinase inhibitor, with an IC_{50} of 19.9 nM. Antineoplastic activities.



Purity: 99.70%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Simotinib hydrochloride

Cat. No.: HY-101820A

Simotinib hydrochloride is a selective, specific, and orally bioavailable **EGFR** tyrosine kinase inhibitor, with an IC_{50} of 19.9 nM. Antineoplastic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SU5204

Cat. No.: HY-126319

SU5204, a tyrosine kinase inhibitor, has IC_{50}s of 4 and 51.5 μM for **FLK-1 (VEGFR-2)** and **HER2**, respectively.



Purity: 98.89%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Sulforaphene

Cat. No.: HY-N2450

Sulforaphene, isolated from radish seeds, exhibits an ED_{50} against velvetleaf seedlings approximately 2 x 10^{-4} M. Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting **EGFR**, **p-ERK1/2**, **NFκB** and other signals.



Purity: 99.26%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Sunvozertinib

(DZD9008)

Cat. No.: HY-132842

Sunvozertinib (DZD9008) is a potent **ErbBs** (EGFR, Her2, especially mutant forms) and **BTK** inhibitor.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK-285

Cat. No.: HY-15196

TAK-285 is a potent, selective, ATP-competitive and orally active **HER2** and **EGFR(HER1)** inhibitor with **IC_{50}** of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for **HER1/2** than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.



Purity: 98.04%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tarlox-TKI

Cat. No.: HY-43533

Tarlox-TKI, the active metabolite of Tarloxotinib, is an irreversible pan-**ErbB** TKI (Tarlox-TKI).



Purity: 96.93%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg

Tarloxotinib bromide

(TH-4000)

Cat. No.: HY-17632

Tarloxotinib bromide (TH-4000) is an irreversible **EGFR/HER2** inhibitor.



Purity: 99.26%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAS0728

Cat. No.: HY-111553

TAS0728 is a potent, selective, orally active, irreversible and covalent-binding **HER2** inhibitor, binds to HER2 at C805, inhibits its kinase activity, with an **IC_{50}** of 13 nM.



Purity: 99.15%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TAS6417

(CLN-081)

Cat. No.: HY-112299

TAS6417 (CLN-081) is a highly effective, orally active and **pan-mutation-selective EGFR** tyrosine kinase inhibitor with a unique scaffold fitting into the ATP-binding site of the EGFR hinge region, with **IC_{50}** values ranging from 1.1-8.0 nM.



Purity: 98.77%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tephrosin

(Deguelinol I; Hydroxydeguelin)

Cat. No.: HY-N1166

Tephrosin is a natural rotenoid which has potent antitumor activities. Tephrosin induces degradation of of **EGFR** and **ErbB2** by inducing internalization of the receptors.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tesevatinib

(XL-647; EXEL-7647; KD-019)

Cat. No.: HY-13314

Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits **EGFR**, **ErbB2**, **KDR**, **Flt4** and **EphB4** kinase with **IC_{50}**s of 0.3, 16, 1.5, 8.7, and 1.4 nM.



Purity: 99.21%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg

Tezatabep matraxetan

Cat. No.: HY-139565

Tezatabep matraxetan is a radiolabeled polypeptide used for diagnosis and research of cancer characterized by overexpression of **HER2**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Theliatinib

(Xiliertinib; HMPL-309) Cat. No.: HY-104066

Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective **EGFR** inhibitor with a K_i of 0.05 nM and an IC_{50} of 3 nM. Theliatinib has an IC_{50} of 22 nM for **EGFR T790M/L858R mutant**.



Purity: 99.88%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Trastuzumab

(Anti-Human HER2, Humanized Antibody) Cat. No.: HY-P9907

Trastuzumab is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

Trastuzumab

Purity: 99.80%
Clinical Data: Launched
Size: 1 mg, 5 mg, 25 mg, 50 mg

Trastuzumab deruxtecan

(DS-8201; DS-8201a) Cat. No.: HY-138298A

Trastuzumab deruxtecan (DS-8201a) is an anti-**human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)**.

Trastuzumab deruxtecan

Purity: ≥99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Trastuzumab deruxtecan (solution)

(DS-8201 (solution); DS-8201a (solution)) Cat. No.: HY-138298

Trastuzumab deruxtecan (DS-8201a) (solution) is an anti-**human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC)**.

Trastuzumab deruxtecan

Purity: 98.75%
Clinical Data: Launched
Size: 5 mg (10 mg × mL * 500 μL in Aqμeoμs solμtion)

Trastuzumab emtansine

(Ado-Trastuzumab emtansine; PRO132365; T-DM 1) Cat. No.: HY-P9921

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine).

Trastuzumab emtansine

Purity: ≥99.40%
Clinical Data: Launched
Size: 1 mg, 5 mg, 10 mg

Tucatinib

(Irbinitinib; ARRY-380; ONT-380) Cat. No.: HY-16069

Tucatinib (Irbinitinib) is a potent, orally active and selective **HER2** inhibitor with an IC_{50} of 8 nM.



Purity: 99.82%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 500 mg

Tucatinib hemiethanolate (Irbinitinib hemiethanolate; ARRY-380 hemiethanolate; ONT-380 hemiethanolate)

Cat. No.: HY-16069A

Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective **HER2** inhibitor with an IC_{50} of 8 nM.



Purity: 99.45%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tuxobertinib

(BDTX-189) Cat. No.: HY-136789

Tuxobertinib (BDTX-189) is a potent, orally active and selective inhibitor of allosteric **EGFR** and **HER2** oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. Tuxobertinib shows K_Ds of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity.



Purity: 99.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TX1-85-1

Cat. No.: HY-100848

TX1-85-1 is an irreversible **Her3 (ErbB3)** inhibitor with an IC_{50} of 23 nM. TX1-85-1 is also the first selective **Her3 ligand**, which forms a covalent bond with Cys721 located in the ATP-binding site of Her3.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Tyrphostin 23

(Tyrphostin A23; RG-50810; AG 18) Cat. No.: HY-15644

Tyrphostin 23 (Tyrphostin A23) is an **EGFR** inhibitor with an IC_{50} and K_i of 35 and 11 μM, respectively.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Tyrphostin 25

(AG82; Tyrphostin A 25; Tyrphostin AG 82; RG-50875)

Cat. No.: HY-101958

Tyrphostin 25 (AG82) is a specific inhibitor of the **EGFR tyrosine kinase**. Tyrphostin 25 is also a **GPR35** agonist with an IC_{50} of 0.94 μM and an EC_{50} of 5.3 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrphostin 8

Cat. No.: HY-W174279

Tyrphostin 8 is a **tyrosine kinase**, with an IC_{50} of 560 μM for **EGFR kinase**. Tyrphostin 8 is also a **GTPase** inhibitor. Tyrphostin 8 can inhibit the protein **serine/threonine phosphatase calcineurin** (IC_{50}=21 μM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrphostin AG 112

Cat. No.: HY-112474

Tyrphostin AG 112 is an **EGFR phosphorylation** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyrphostin AG 528

(Tyrphostin B66; AG 528)

Cat. No.: HY-100499

Tyrphostin AG 528 is an inhibitor of **EGFR** and **ErbB2** with IC_{50}s of 4.9 and 2.1 μM, respectively. Tyrphostin AG 528 (Tyrphostin B66) is a protein tyrosine kinase inhibitor, with IC_{50}s of 4.9 μM for **epidermal growth factor receptors (EGFR)** and 2.1 μM for **ErbB2**.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG 879

(AG 879)

Cat. No.: HY-20878

Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits **TrKA** phosphorylation (IC_{50} of 10 μM), but not TrKB and TrKC.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyrphostin AG30

(AG30)

Cat. No.: HY-118532

Tyrphostin AG30 (AG30) is a potent and selective **EGFR tyrosine kinase** inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts.



Purity: 98.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Varlitinib

(ASLAN001; ARRY-334543)

Cat. No.: HY-10530

Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-**EGFR** inhibitor with IC_{50}s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.



Purity: 96.66%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

VEGFR-IN-1

Cat. No.: HY-101219

VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC_{50}s of 0.02, 0.18, 0.24 7.3, and 7 μM for **KDR**, **Flt-1**, c-Kit, EGF-R, and c-Src, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WHI-P154

Cat. No.: HY-13895

WHI-P154 is a potent **EGFR** inhibitor, and also modestly blocks **JAK3**, with IC_{50}s of 4 nM and 1.8 μM, respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

WHI-P180

(Janex 3)

Cat. No.: HY-15769

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with IC_{50}s of 5 nM, 66 nM and 4 μM, respectively.



Purity: 99.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

WHI-P180 hydrochloride

(Janex 3 hydrochloride;)

Cat. No.: HY-15769A

WHI-P180 (Janex 3) is a multi-kinase inhibitor; inhibits **RET**, **KDR** and **EGFR** with IC_{50}s of 5 nM, 66 nM and 4 μM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

WZ-3146

Cat. No.: HY-12001

WZ3146 is a mutant selective **EGFR** inhibitor with IC_{50}s of 2, 2, 5, 14 and 66 nM for $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{E746\_A750}$, $EGFR^{E746\_A750/T790M}$ and EGFR, respectively.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

WZ4002

Cat. No.: HY-12026

WZ4002 is a mutant selective **EGFR** inhibitor with IC_{50}s of 2, 8, 3 and 2 nM for $EGFR^{L858R}$, $EGFR^{L858R/T790M}$, $EGFR^{E746\_A750}$ and $EGFR^{E746\_A750/T790M}$, respectively.



Purity: 99.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

WZ8040

Cat. No.: HY-12029

WZ8040 is an irreversible mutated **EGFR T790M** inhibitor and inhibits **EGFR phosphorylation**. WZ8040 displays 100-fold greater activity against the mutated EGFR than the normal.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ZD-4190

Cat. No.: HY-U00002

ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (**VEGFR2**) and of epidermal growth factor receptor (**EGFR**) signalling, used for the treatment of cancer.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

Zorifertinib

(AZD3759)

Cat. No.: HY-18750

Zorifertinib (AZD3759) is a potent, orally active, central nervous system-penetrant, **EGFR** inhibitor. At K_m ATP concentrations, the IC_{50}s are 0.3, 0.2, and 0.2 nM for $EGFR^{wt}$, $EGFR^{L858R}$, and $EGFR^{exon\ 19Del}$, respectively.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

β-Hydroxyisovalerylshikonin

Cat. No.: HY-N4201

Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of **protein tyrosine kinases (PTK)**, with IC_{50}s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK

Janus kinase

Janus kinase (JAK) is a family of intracellular, nonreceptor tyrosine kinases that transduce cytokine-mediated signals via the JAK-STAT pathway. Since members of the type I and type II cytokine receptor families possess no catalytic kinase activity, they rely on the JAK family of tyrosine kinases to phosphorylate and activate downstream proteins involved in their signal transduction pathways. The receptors exist as paired polypeptides, thus exhibiting two intracellular signal-transducing domains. JAKs associate with a proline-rich region in each intracellular domain, which is adjacent to the cell membrane and called a box1/box2 region. After the receptor associates with its respective cytokine/ligand, it goes through a conformational change, bringing the two JAKs close enough to phosphorylate each other. The JAK autophosphorylation induces a conformational change within itself, enabling it to transduce the intracellular signal by further phosphorylating and activating transcription factors called STATs. The activated STATs dissociate from the receptor and form dimers before translocating to the cell nucleus, where they regulate transcription of selected genes.

(2R,5S)-Ritlecitinib

((2R,5S)-PF-06651600)

Cat. No.: HY-100754B

(2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective **JAK3** inhibitor (IC_{50}=144.8 nM) extracted from patent US20150158864A1, example 68.



Purity: 98.83%
Clinical Data: No Development Reported
Size: 5 mg

(3R,4S)-Tofacitinib

Cat. No.: HY-40354D

(3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with IC_{50} of 1 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

(3S,4R)-Tofacitinib

Cat. No.: HY-40354B

(3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with IC_{50} of 1 nM.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

(3S,4S)-Tofacitinib

Cat. No.: HY-40354C

(3S,4S)-Tofacitinib is the less active S-enantiomer of Tofacitinib. Tofacitinib inhibits **JAK3** with IC_{50} of 1 nM.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 1 mg

(E/Z)-AG490

((E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42)

Cat. No.: HY-107459

(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a **tyrosine kinase** inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-Zotiraciclib

((E/Z)-TG02; (E/Z)-SB1317)

Cat. No.: HY-15166

(E/Z)-Zotiraciclib ((E/Z)-TG02) is a potent inhibitor of **CDK2**, **JAK2**, and **FLT3**. (E/Z)-Zotiraciclib ((E/Z)-TG02) can be used for the research of cancer.



Purity: 99.96%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

(E/Z)-Zotiraciclib citrate

((E/Z)-TG02 citrate; (E/Z)-SB1317 citrate)

Cat. No.: HY-15166B

(E/Z)-Zotiraciclib citrate is a potent **CDK2**, **JAK2**, and **FLT3** inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

(E/Z)-Zotiraciclib hydrochloride

((E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride)

Cat. No.: HY-15166A

(E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent **CDK2**, **JAK2**, and **FLT3** inhibitor.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

(Rac)-Ruxolitinib-d9

((Rac)-INCB18424-d9)

Cat. No.: HY-W062703S

(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide

Cat. No.: HY-120469

GDC-046 is a potent, selective, and orally bioavailable **TYK2** inhibitor with K_is of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Abrocitinib

(PF-04965842) Cat. No.: HY-107429

Abrocitinib (PF-04965842) is a potent, orally active and selective **JAK1** inhibitor, with IC_{50}s of 29 and 803 nM for JAK1 and JAK2, respectively.



Purity: 99.26%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AG490

(Tyrphostin AG490; Tyrphostin B42) Cat. No.: HY-12000

AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

AMG-47a

Cat. No.: HY-18303

AMG-47a is a potent and orally active **lymphocyte-specific protein tyrosine kinase (Lck)** inhibitor, with an IC_{50} of 0.2 nM. AMG-47a also inhibits **VEGF2**, **p38α**, **Jak3** and **MLR** and **IL-2** with IC_{50}s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively.



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AT9283

Cat. No.: HY-50514

AT9283 is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B**, **JAK2/3**, **Abl (T315I)** and **Flt3** (IC_{50}s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Atractylenolide I

Cat. No.: HY-N0201

Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

AZ-3

Cat. No.: HY-112442

AZ-3 is a potent and selective **JAK1** inhibitor with an IC_{50} of 34 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZ960

Cat. No.: HY-10411

AZ960 is a potent and specific inhibitor of the **JAK2** kinase with a K_i of 0.45 nM.



Purity: 97.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

AZD-1480

Cat. No.: HY-10193

AZD-1480 is an ATP-competitive inhibitor of **JAK1** and **JAK2** with IC_{50}s of 1.3 nM and <0.4nM, respectively.



Purity: 99.37%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AZD4604

(JAK1-IN-7) Cat. No.: HY-126294

AZD4604 (JAK1-IN-7) is a **Janus-associated kinase 1 (JAK1)** inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Baricitinib

(LY3009104; INCB028050) Cat. No.: HY-15315

Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable **JAK1** and **JAK2** inhibitor with IC_{50}s of 5.9 nM and 5.7 nM, respectively.



Purity: 99.97%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Baricitinib phosphate

(LY3009104 phosphate; INCB028050 phosphate) Cat. No.: HY-15315A

Baricitinib phosphate (LY3009104 phosphate; INCB028050 phosphate) is a selective orally bioavailable **JAK1/JAK2** inhibitor with IC_{50} of 5.9 nM and 5.7 nM, respectively.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Baricitinib-d3

(LY3009104-d3; INCB028050-d3) Cat. No.: HY-15315S1

Baricitinib-d3 (LY3009104-d3) is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable **JAK1** and **JAK2** inhibitor with IC_{50}s of 5.9 nM and 5.7 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Baricitinib-d5

(LY3009104-d5; INCB028050-d5) Cat. No.: HY-15315S

Baricitinib-d5 (LY3009104-d5) is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable **JAK1** and **JAK2** inhibitor with IC_{50}s of 5.9 nM and 5.7 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BD750

Cat. No.: HY-131140

BD750, an effective immunosuppressant and a **JAK3/STAT5** inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC_{50} values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BMS-066

Cat. No.: HY-18710

BMS-066 is an **IKKβ/Tyk2** pseudokinase inhibitor, with **IC_{50}s** of 9 nM and 72 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BMS-911543

Cat. No.: HY-15270

BMS-911543 is a selective **JAK2** inhibitor, with **IC_{50}**s of 1.1 nM, less selective at JAK1, JAK3 and TYK2 (**IC_{50}**, 75, 360, 66 nM, respectively).



Purity: 98.05%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

BMS-986202

Cat. No.: HY-131968

BMS-986202 is a potent, selective and orally active **Tyk2** inhibitor that binds to **Tyk2 JH2** with an **IC_{50}** of 0.19 nM and a **K_i** of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members.



Purity: 99.46%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Brepocitinib

(PF-06700841) Cat. No.: HY-112708

Brepocitinib (PF-06700841) is a potent dual **Janus kinase 1 (JAK1)** and **TYK2** inhibitor with **IC_{50}**s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits **JAK2** and **JAK3** with IC_{50}s of 77 nM and 6.49 μM, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Brepocitinib P-Tosylate

(PF-06700841 P-Tosylate) Cat. No.: HY-112708A

Brepocitinib (PF-06700841) P-Tosylate is a potent dual **Janus kinase 1 (JAK1)** and **TYK2** inhibitor with **IC_{50}**s of 17 nM and 23 nM, respectively. Brepocitinib P-Tosylate also inhibits **JAK2** and **JAK3** with IC_{50}s of 77 nM and 6.49 μM, respectively.



Purity: 99.69%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Brevilin A

Cat. No.: HY-N2959

Brevilin A is a sesquiterpene lactone isolated from Centipeda minima with anti-tumor activity. Brevilin A is a selective inhibitor of **JAK-STAT** signal pathway by attenuating the JAKs activity and blocking STAT3 signaling (**IC_{50}** = 10.6 μM) in Cancer Cells.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

CEP-1347

(KT7515)

Cat. No.: HY-10412

CEP-1347 is an inhibitor of the **JNK/SAPK** pathway with neuroprotective effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

CEP-33779

Cat. No.: HY-15343

CEP-33779 is a novel, selective, and orally bioavailable inhibitor of **JAK2** with an IC_{50} of 1.8±0.6 nM.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cerdulatinib

(PRT062070; PRT2070)

Cat. No.: HY-15999

Cerdulatinib (PRT062070) is a selective **Tyk2** inhibitor with an IC_{50} of 0.5 nM. Cerdulatinib (PRT062070) also is a dual **JAK** and **SYK** inhibitor with IC_{50}s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.



Purity: 99.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Cerdulatinib hydrochloride

(PRT062070 hydrochloride; PRT2070 hydrochloride)

Cat. No.: HY-15999A

Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual **SYK** and **JAK**, with IC_{50}s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for **SYK** and **Tyk2**, **JAK1**, **2**, **3**, respectively.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CHZ868

Cat. No.: HY-18960

CHZ868 is a type II **JAK2** inhibitor with an IC_{50} of 0.17 μM in EPOR JAK2 WT Ba/F3 cell.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Coumermycin A1

Cat. No.: HY-N7452

Coumermycin A1 is a **JAK2 signal** activator. Coumermycin A1 inhibits **DNA Gyrase** which thereby inhibits cell division in bacteria.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg

Cucurbitacin I

(Elatericin B; JSI-124; NSC-521777)

Cat. No.: HY-N1405

Cucurbitacin I is a natural selective inhibitor of **JAK2/STAT3**, with potent anti-cancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Curculigoside

Cat. No.: HY-N0705

Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritic effects in vivo and in vitro via regulation of the **JAK/STAT/NF-κB** signaling pathway.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Debio 0617B

Cat. No.: HY-108417

Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML $CD34^+$ stem/progenitor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Decernotinib

(VX-509; VRT-831509)

Cat. No.: HY-12469

Decernotinib is a potent, orally active **JAK3** inhibitor, with K_is of 2.5, 11, 13 and 11 nM for **JAK3**, JAK1, JAK2, and TYK2, respectively.



Purity: 99.67%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg

Dehydrocrenatidine

(Kumujian G; O-Methylpicrasidine I) Cat. No.: HY-N3710

Dehydrocrenatidine, a natural alkaloid, is a specific **JAK** inhibitor. Dehydrocrenatidine inhibits voltage-gated sodium channels and ameliorates mechanic allodia in a rat model of neuropathic pain.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Delgocitinib

(JTE-052) Cat. No.: HY-109053

Delgocitinib (JTE-052) is a specific **JAK** inhibitor with **IC_{50}**s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.



Purity: 99.76%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Delphinidin chloride

Cat. No.: HY-N2409

Delphinidin chloride, an anthocyanidin, is isolated from berries and red wine. Delphinidin chloride shows endothelium-dependent vasorelaxation. Delphinidin chloride also can modulate JAK/STAT3 and MAPKinase signaling to induce apoptosis in HCT116 cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Deucravacitinib

(BMS-986165) Cat. No.: HY-117287

Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric **TYK2** inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (**IC_{50}**=1.0 nM) and blocks receptor-mediated Tyk2 activation by...



Purity: 99.79%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg

Deuruxolitinib

(CTP-543; Ruxolitinib D8; Deuterated Ruxolitinib) Cat. No.: HY-50856S

Deuruxolitinib (CTP-543), a deuterated Ruxolitinib, modulates the activity of JAK1/JAK2. Deuruxolitinib can be used for the research hair loss disorders (from patent WO2017192905A1, compound I).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DTP3

Cat. No.: HY-100538

DTP3 TFA is a potent and selective **GADD45β/MKK7** inhibitor. DTP3 TFA targets an essential, cancer-selective cell-survival module downstream of the NF-κB pathway.



Purity: 99.43%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fedratinib

(TG-101348; SAR 302503) Cat. No.: HY-10409

Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active **JAK2** inhibitor with **IC_{50}**s of 3 nM for both **JAK2** and **JAK2V617F kinase**. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 100 mg, 200 mg, 500 mg, 1 g

Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate)

Cat. No.: HY-10409A

Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active **JAK2** inhibitor with **IC_{50}**s of 3 nM for both **JAK2** and **JAK2V617F kinase**.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 100 mg, 200 mg, 500 mg, 1 g

Filgotinib

(GLPG0634) Cat. No.: HY-18300

Filgotinib (GLPG0634) is a selective and orally active **JAK1** inhibitor with **IC_{50}** of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.



Purity: 99.37%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Filgotinib-d4

(GLPG0634-d4) Cat. No.: HY-18300S

Filgotinib-d4 (GLPG0634-d4) is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective **JAK1** inhibitor with **IC_{50}** of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg

FLLL32

Cat. No.: HY-100544

FLLL32, a synthetic analog of curcumina, is a **JAK2/STAT3** dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FM-381

Cat. No.: HY-102046

FM-381 is a potent covalent reversible inhibitor of **JAK3** targeting the unique Cys909. FM-381 has an IC_{50} of 127 pM for JAK3, with 410, 2700 and 3600-fold selectivity over JAK1, JAK2 and TYK2, respectively.



Purity: 98.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

FM-479

Cat. No.: HY-131014

FM-479 is the **negative control** of FM-381 (HY-102046) and has no activity on JAK3 or other kinases. FM-381 is a potent covalent reversible inhibitor of **JAK3** targeting the unique Cys909.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Fosifidancitinib

Cat. No.: HY-109175

Fosifidancitinib is a potent and selective inhibitor of **JAK kinases 1/3**. Fociatinib is used in studies of allergies, asthma and autoimmune diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

G5-7

Cat. No.: HY-115452

G5-7, an orally active and allosteric **JAK2** inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr^{1068}) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect.



Purity: 99.84%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Gandotinib

(LY2784544)

Cat. No.: HY-13034

Gandotinib (LY2784544) is a potent **JAK2** inhibitor with IC_{50} of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC_{50} of 4, 25, 32, 44, and 95 nM.



Purity: 99.82%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GDC-4379

Cat. No.: HY-139837

GDC-4379 is a **JAK1** inhibitor that can be used for the research of asthma.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ginsenoside Rk1

Cat. No.: HY-N2515

Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of **Jak2/Stat3** signaling pathway and **NF-κB**.



Purity: 99.90%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

GLPG0634 analog

Cat. No.: HY-13961

GLPG0634 (analog) (compound176)is a pan JAK inhibitor with IC50s of 50-200 nM for JAK1/JAK2/JAK3; more information can be found in the reference patents.



Purity: 98.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Golidocitinib

(AZD4205)

Cat. No.: HY-107361

Golidocitinib (AZD4205) is a selective **JAK1** inhibitor, with an IC_{50} of 73 nM, weakly inhibits JAK2 (IC_{50}>14.7 μM), and shows little inhibition on JAK3 (IC_{50}>30 μM).



Purity: 99.75%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

GSK2646264

Cat. No.: HY-112809

GSK2646264 (Compound 44) is a potent and selective **spleen tyrosine kinase (SYK)** inhibitor with a **pIC$_{50}$** of 7.1.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gusacitinib

(ASN-002)

Cat. No.: HY-103018

Gusacitinib (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (**SYK**) and janus kinase (**JAK**) with **IC$_{50}$** values of 5-46 nM. Gusacitinib has anti-cancer activity in both solid and hematological tumor types.



Purity: 99.41%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ifidancitinib

(ATI-50002; ATI-502)

Cat. No.: HY-109178

Ifidancitinib (ATI-50002) is a potent and selective inhibitor of **JAK kinases 1/3**. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ilginatinib

(NS-018)

Cat. No.: HY-19631A

Ilginatinib (NS-018) is a highly active and orally bioavailable **JAK2** inhibitor, with an **IC$_{50}$** of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (**IC$_{50}$**, 33 nM), JAK3 (**IC$_{50}$**, 39 nM), and Tyk2 (**IC$_{50}$**, 22 nM).



Purity: 99.15%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ilginatinib hydrochloride

(NS-018 hydrochloride)

Cat. No.: HY-19631B

Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable **JAK2** inhibitor, with an **IC$_{50}$** of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (**IC$_{50}$**, 33 nM), JAK3 (**IC$_{50}$**, 39 nM), and Tyk2 (**IC$_{50}$**, 22 nM).



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ilginatinib maleate

(NS-018 maleate)

Cat. No.: HY-19631

Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable **JAK2** inhibitor, with an **IC$_{50}$** of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (**IC$_{50}$**, 33 nM), JAK3 (**IC$_{50}$**, 39 nM), and Tyk2 (**IC$_{50}$**, 22 nM).



Purity: 97.04%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ilunocitinib

Cat. No.: HY-132819

Ilunocitinib (compound 27) is a **JAK** inhibitor (extracted from patent WO2009114512A1).



Purity: 98.01%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Itacitinib

(INCB039110)

Cat. No.: HY-16997

Itacitinib (INCB039110) is an orally active and selective inhibitor of **JAK1** with an **IC$_{50}$** of 2 nM for **human JAK1**. Itacitinib shows >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Itacitinib adipate

Cat. No.: HY-16997A

Itacitinib adipate is an orally bioavailable and selective **JAK1** inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Itacnosertib

(TP-0184) Cat. No.: HY-109179

Itacnosertib (TP-0184) is both inhibitor to **JAK2**, **ACVR1 (ALK2)** and **ALK5** as described in WO2014151871.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Izencitinib

(TD-1473; JNJ-8398) Cat. No.: HY-109148

Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted **JAK** inhibitor. Izencitinib (TD-1473) can be used in the study for ulcerative colitis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK-2/3-IN-1

Cat. No.: HY-10652

JAK-2/3-IN-1 is a potent **JAK-2** and **JAK-3** inhibitor extracted from patent US8163732B2, compound 46, has K_is of <250 nM for both isoforms.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-1

Cat. No.: HY-13827

JAK-IN-1 is a **JAK1/2/3** inhibitor with IC_{50}s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-10

Cat. No.: HY-U00277

JAK-IN-10 is a **JAK** inhibitor. JAK-IN-10 can be used for the research of dry eye disorders.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-11

Cat. No.: HY-U00318

JAK-IN-11 is a potent and selective **JAK** inhibitor extracted from patent WO2012122452A1, Compound II, has the potential for the skin disorders (such as cutaneous lupus) treatment.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-14

Cat. No.: HY-139807

JAK-IN-14 is a potent and selective **JAK1** inhibitor, with an IC_{50} of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16).



Purity: 98.72%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

JAK-IN-15

Cat. No.: HY-46262

JAK-IN-15 is a **JAK** inhibitor. WO2016119700A1 (Compound 15).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-17

Cat. No.: HY-144057

JAK-IN-17 is a potent inhibitor of **JAK**. JAK-IN-17 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2021185305A1, compound 9-1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-18

Cat. No.: HY-144058

JAK-IN-18 is a potent inhibitor of **JAK**. JAK-IN-18 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2018204238A1, compound 1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-19

Cat. No.: HY-144075

JAK-IN-19 is a potent **JAK** inhibitor (PBMC IFNγ **pIC_{50}**=7.2 and HLF Eotaxin **pIC_{50}**=7.7). JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 **pIC_{50}**=7.0, Aurora B **pIC_{50}**=5.8).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-20

Cat. No.: HY-143444

JAK-IN-20 is a potent, pan and orally active **JAK** inhibitor with an **IC_{50}**s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-3

Cat. No.: HY-111750

JAK-IN-3 (compound 22) is a potent **JAK** inhibitor, with **IC_{50}** values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK-IN-4

Cat. No.: HY-111749

JAK-IN-4 is a prodrug of a **JAK** inhibitor, effective in murine collagen induced arthritis model.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK-IN-5

Cat. No.: HY-111471

JAK-IN-5 is an inhibitor of **JAK** extracted from patent US20170121327A1, compound example 283.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK-IN-5 hydrochloride

Cat. No.: HY-111471A

JAK-IN-5 hydrochloride is an inhibitor of **JAK** extracted from patent US20170121327A1, compound example 283.



Purity: 99.54%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK/HDAC-IN-1

Cat. No.: HY-126141

JAK/HDAC-IN-1 is a potent **JAK2/HDAC** dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows **IC_{50}**s of 4 and 2 nM for JAK2 and HDAC, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

JAK1-IN-4

Cat. No.: HY-116505

JAK1-IN-4 is a potent and selective **JAK1** inhibitor, with **IC_{50}**s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC_{50}, 227 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK1-IN-8

Cat. No.: HY-139423

JAK1-IN-8, a potent **JAK1** inhibitor (**IC_{50}**<500 nM), compound 28, extracted from patent WO2016119700A1.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK1-IN-9

Cat. No.: HY-144440

JAK1-IN-9 (compound 23a) is a potent and selective **JAK1** inhibitor with an **IC_{50}** of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK1/TYK2-IN-1

Cat. No.: HY-145336

JAK1/TYK2-IN-1 is a dual inhibitor of **TYK2** and **JAK1** (IC_{50} = 29 and 41 nM respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK1/TYK2-IN-3

Cat. No.: HY-143885

JAK1/TYK2-IN-3 is a potent, selective and orally active dual **TYK2/JAK1** inhibitor with IC_{50} values of 6 and 37 nM, respectively. JAK1/TYK2-IN-3 also shows selectively relative to **JAK2** (IC_{50}=140 nM) and **JAK3** (IC_{50}=362 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK2-IN-4

Cat. No.: HY-100759

JAK2-IN-4 (compound 16h) is a selective **JAK2/JAK3** inhibitor, with IC_{50} values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK2-IN-6

Cat. No.: HY-137756

JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective **JAK2** inhibitor with an IC_{50} of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK2-IN-7

Cat. No.: HY-131906

JAK2-IN-7 is a selective **JAK2** inhibitor with IC_{50}s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/$F3^{V617F}$ cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JAK2/FLT3-IN-1

Cat. No.: HY-130247

JAK2/FLT3-IN-1 is a potent and orally active dual **JAK2/FLT3** inhibitor with IC_{50} values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 has anti-cancer activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK2/FLT3-IN-1 TFA

Cat. No.: HY-130247A

JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual **JAK2/FLT3** inhibitor with IC_{50} values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity.



Purity: 98.94%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

JAK2/TYK2-IN-1

Cat. No.: HY-143884

JAK2/TYK2-IN-2 is a potent and selective **TYK2** inhibitor with IC_{50} values of 9 and 157 nM for **TYK2** and **JAK2**, respectively. JAK2/TYK2-IN-2 has anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3 covalent inhibitor-1

Cat. No.: HY-119935

JAK3 covalent inhibitor-1 is a potent and selective **janus kinase 3 (JAK3)** covalent inhibitor with an IC_{50} of 11 nM and shows 246-fold selectivity vs other JAKs.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3-IN-1

Cat. No.: HY-19544

JAK3-IN-1 is a potent, selective and orally active **JAK3** inhibitor with an IC_{50} of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for **JAK3** than JAK1 (IC_{50} of 896 nM) and JAK2 (IC_{50} of 1050 nM).



Purity: 99.23%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

JAK3-IN-11

Cat. No.: HY-146727

JAK3-IN-11 (Compound 12), a potent, noncytotoxic, irreversible, orally active **JAK3** inhibitor with IC_{50} value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3-IN-6

Cat. No.: HY-101976

JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC_{50} of 0.15 nM.



Purity: 98.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

JAK3-IN-7

Cat. No.: HY-U00390

JAK3-IN-7 is a potent and selective **JAK3** inhibitor extracted from patent WO2011013785A1, has an IC_{50} of <0.01 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-1

Cat. No.: HY-143716

JAK3/BTK-IN-1 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-2

Cat. No.: HY-143717

JAK3/BTK-IN-2 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-3

Cat. No.: HY-143718

JAK3/BTK-IN-3 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-4

Cat. No.: HY-143719

JAK3/BTK-IN-4 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JAK3/BTK-IN-5

Cat. No.: HY-143720

JAK3/BTK-IN-5 is a potent inhibitor of **JAK3/BTK**. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

JANEX-1

(WHI-P131; Jak3 inhibitor I)

Cat. No.: HY-15508

JANEX-1 (WHI-P131) is a potent and specific **JAK3** inhibitor (estimated K_i=2.3 μM). JANEX-1 (WHI-P131) shows potent JAK3-inhibitory activity (IC_{50} of 78 μM), does not inhibit JAK1 and JAK2.



Purity: 99.60%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lestaurtinib

(CEP-701; KT-5555)

Cat. No.: HY-50867

Lestaurtinib (CEP-701;KT-5555) is an ATP-competitive multi-kinase inhibitor with potent activity against the Trk family of receptor tyrosine kinases. Lestaurtinib inhibits **JAK2**, **FLT3** and **TrkA** with IC_{50}s of 0.9, 3 and less than 25 nM, respectively.



Purity: 99.92%
Clinical Data: Phase 3
Size: 5 mg

LFM-A13

Cat. No.: HY-18009

LFM-A13 is a potent **BTK**, **JAK2**, **PLK** inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC_{50}s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Lorpucitinib

(JNJ-64251330)

Cat. No.: HY-109182

Lorpucitinib is a Gut-Restricted **JAK** Inhibitor for the research of Inflammatory Bowel Disease.



Purity: 99.97%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Momelotinib

(CYT387)

Cat. No.: HY-10961

Momelotinib (CYT387) is an ATP-competitive inhibitor of **JAK1/JAK2** with IC_{50}a of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3.



Purity: 98.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Momelotinib Mesylate

(CYT387 Mesylate)

Cat. No.: HY-10963

Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of **JAK1/JAK2** with IC_{50} of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

Momelotinib sulfate

(CYT387 sulfate salt)

Cat. No.: HY-10962

Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of **JAK1/JAK2** with IC_{50} of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC_{50}=155 nM).



Purity: 98.04%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Nezulcitinib

(TD-0903)

Cat. No.: HY-132849

Nezulcitinib (TD-0903) is an inhaled and lung-selective pan-Janus kinase (**JAK**) inhibitor. Nezulcitinib can be used for the research of COVID-19 associated acute lung injury and impaired oxygenation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC 33994

Cat. No.: HY-18293

NSC 33994 (G6) is a selective **JAK2** inhibitor, with an IC_{50} of 60 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NSC 42834

(JAK2 Inhibitor V; Z3)

Cat. No.: HY-15480

NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of **Jak2**, inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.



Purity: 96.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BSK805

Cat. No.: HY-14722

NVP-BSK805 is an ATP-competitive **JAK2** inhibitor, with IC_{50}s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

NVP-BSK805 dihydrochloride

Cat. No.: HY-14722A

NVP-BSK805 dihydrochloride is an ATP-competitive **JAK2** inhibitor, with IC_{50}s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.



Purity: 99.36%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NVP-BSK805 trihydrochloride

Cat. No.: HY-14722C

NVP-BSK805 trihydrochloride trihydrochloride is an ATP-competitive **JAK2** inhibitor, with IC_{50}s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Oclacitinib maleate

(PF-03394197 maleate)

Cat. No.: HY-13577A

Oclacitinib maleate (PF-03394197 maleate) is a novel **JAK** inhibitor. Oclacitinib maleate (PF-03394197 maleate) is most potent at inhibiting **JAK1** (IC_{50}=10 nM).



Purity: 99.65%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Pacritinib

(SB1518)

Cat. No.: HY-16379

Pacritinib (SB1518) is a potent inhibitor of both wild-type **JAK2** (IC_{50}=23 nM) and **JAK2**^{V617F} mutant (IC_{50}=19 nM). Pacritinib also inhibits **FLT3** (IC_{50}=22 nM) and its mutant **FLT3**^{D835Y} (IC_{50}=6 nM).



Purity: 99.93%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Peficitinib

(ASP015K; JNJ-54781532)

Cat. No.: HY-19568

Peficitinib is an oral **JAK** inhibitor, with IC_{50}s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively.



Purity: 99.78%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PF-06263276

Cat. No.: HY-101024

PF-06263276 (PF 6263276) is a potent and selective **pan-JAK** inhibitor, with IC_{50}s of 2.2 nM, 23.1 nM, 59.9 nM and 29.7 nM for JAK1, JAK2, JAK3 and TYK2, respectively.



Purity: ≥99.0%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Povorcitinib

Cat. No.: HY-145588

Povorcitinib is a potent and selective inhibitor of **JAK1**. Povorcitinib has the potential for the research of disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) (extracted from patent WO2021076124A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Protosappanin A

(PTA)

Cat. No.: HY-113573

Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses **JAK2/STAT3**-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.



Purity: 99.98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

Pyridone 6

Cat. No.: HY-14435

Pyridone 6 is a **pan-JAK** inhibitor, which potently inhibits the JAK kinase family, with IC_{50}s of 1 nM for **JAK2** and **TYK2**, 5 nM for **JAK3**, and 15 nM for **JAK1**, while displaying significantly weaker affinities (130 nM to >10 mM) for other protein tyrosine kinases.



Purity: 98.84%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Reticuline

Cat. No.: HY-N1356

Reticuline shows anti-inflammatory effects through **JAK2/STAT3** and **NF-κB** signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3. Reticuline exhibits cardiovascular effects.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Reticuline-d3

Cat. No.: HY-N1356S

Reticuline-d3 is the deuterium labeled Reticuline. Reticuline shows anti-inflammatory effects through **JAK2/STAT3** and **NF-κB** signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RGB-286638

Cat. No.: HY-15504

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 99.84%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

RGB-286638 free base

Cat. No.: HY-15504A

RGB-286638 is a **CDK** inhibitor that inhibits the kinase activity of **cyclin T1-CDK9**, **cyclin B1-CDK1**, **cyclin E-CDK2**, **cyclin D1-CDK4**, **cyclin E-CDK3**, and **p35-CDK5** with IC_{50}s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC_{50}s of 3, 5, 50, and 54 nM.



Purity: 98.07%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

Ritlecitinib

(PF-06651600)

Cat. No.: HY-100754

Ritlecitinib (PF-06651600) is an orally active and selective **JAK3** inhibitor with an IC_{50} of 33.1 nM.



Purity: 99.98%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

RO495

Cat. No.: HY-18316

RO495 is a potent inhibitor of non-receptor tyrosine-protein kinase 2 (**TYK2** kinase).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO8191

(CDM-3008; RO4948191)

Cat. No.: HY-W063968

RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent **interferon (IFN) receptor** agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and **JAK/STAT** phosphorylation.

Purity: 98.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Ruxolitinib

(INCB18424)

Cat. No.: HY-50856

Ruxolitinib (INCB18424) is a potent and selective **JAK1/2** inhibitor with IC_{50}s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces **autophagy** and kills tumor cells through toxic **mitophagy**.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ruxolitinib (S enantiomer)

(S-Ruxolitinib; S-INCB18424)

Cat. No.: HY-50856A

Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib S enantiomer is a **JAK** inhibitor.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ruxolitinib phosphate

(INCB018424 phosphate)

Cat. No.: HY-50858

Ruxolitinib phosphate (INCB018424 phosphate) is a potent **JAK1/2** inhibitor with IC_{50}s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Ruxolitinib sulfate

(INCB018424 sulfate)

Cat. No.: HY-50859

Ruxolitinib sulfate (INCB018424 sulfate) is the first potent, selective **JAK1/2** inhibitor to enter the clinic with IC_{50}s of 3.3 nM/2.8 nM, and has > 130-fold selectivity for JAK1/2 versus JAK3.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

SAR-20347

Cat. No.: HY-100895

SAR-20347 is an inhibitor of **TYK2**, **JAK1**, **JAK2** and **JAK3** with IC_{50}s of 0.6, 23, 26 and 41 nM, respectively.



Purity: 98.04%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC99

Cat. No.: HY-124858

SC99 is an orally active, selective **STAT3** inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SD-1008

Cat. No.: HY-107595

SD-1008 is a potent **JAK** inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances **apoptosis** induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SD-1029

Cat. No.: HY-112391

SD-1029 is a **JAK2/STAT3** inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SHR0302

Cat. No.: HY-112724

SHR0302 is a potent and orally active all members of the **JAK family** inhibitor, particularly **JAK1**. The selectivity of SHR0302 for **JAK1** is >10-fold for **JAK2**, 77-fold for **JAK3**, 420-fold for **Tyk2**.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

SJ10542

Cat. No.: HY-145696

SJ10542 is a potent and selective **JAK2/3** directing phenyl glutarimide (PG)-PROTAC with DC_{50}s of 14, 11, and 24 nM for JAK2, JAK3, and JAK2-fusion ALL, respectively. SJ10542 utilizes a PG ligand as the cereblon (CRBN) recruiter.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg

Solcitinib

(GSK-2586184; GLPG-0778)

Cat. No.: HY-16755

Solcitinib is an orally active, competitive, potent, selective **JAK1** inhibitor, with an IC_{50} of 9.8 nM, and 11-, 55- and 23-fold selectivity over JAK2, JAK3 and TYK2, respectively; Solcitinib is used in the research of moderate-to-severe plaque-type psoriasis.



Purity: 99.73%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SYK/JAK-IN-1

Cat. No.: HY-145029

SYK/JAK-IN-1 is dual **SYK/JAK** inhibitor with IC_{50}s of <5 nM for SYK and JAK2, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCJL37

Cat. No.: HY-16640

TCJL37 is a potent, selective, and orally bioavailable **TYK2** inhibitor with a K_i of 1.6 nM. TCJL37 can be used for the research of inflammatory bowel diseases (IBD).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCS 21311

(NIBR3049)

Cat. No.: HY-108264

TCS 21311 (NIBR3049) is a potent, highly selective **JAK3** inhibitor with an IC_{50} of 8 nM, it displays >100-fold selectivity over JAK1, JAK2 and TYK2. TCS 21311 (NIBR3049) inhibits **PKCα**, **PKCθ**, and **GSK3β** with IC_{50}s of 13, 68, and 3 nM, respectively.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Ten01

Cat. No.: HY-139649

Ten01 has 5.0 nM activity against **JAK1** kinase.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TG101209

Cat. No.: HY-10410

TG101209 is a selective **JAK2** inhibitor with IC_{50} of 6 nM, less potent to **Flt3** and **RET** with IC_{50} of 25 nM and 17 nM, appr 30-fold selective for JAK2 than JAK3, and sensitive to JAK2V617F and MPLW515L/K mutations.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tofacitinib

(Tasocitinib; CP-690550)

Cat. No.: HY-40354

Tofacitinib is an orally available **JAK3/2/1** inhibitor with IC_{50}s of 1, 20, and 112 nM, respectively.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tofacitinib citrate

(Tasocitinib citrate; CP-690550 citrate)

Cat. No.: HY-40354A

Tofacitinib citrate is an orally available **JAK1/2/3** inhibitor with IC_{50}s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.



Purity: 99.98%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tofacitinib Prodrug-1

Cat. No.: HY-145829

Tofacitinib Prodrug-1 is an effective and oral active prodrug to mitigate the systemic adverse effects of Tofacitinib. Tofacitinib Prodrug-1 can effectively attenuate the oxazolone-induced colitis in mice model with low toxicity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tofacitinib-13C3

(Tasocitinib-13C3; CP-690550-13C3)

Cat. No.: HY-40354S

Tofacitinib-13C3 (Tasocitinib-13C3) is the 13C-labeled Tofacitinib. Tofacitinib is an orally available **JAK3/2/1** inhibitor with IC_{50}s of 1, 20, and 112 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tofacitinib-d3 citrate

(Tasocitinib-d3 citrate; CP-690550-d3 citrate)

Cat. No.: HY-40354AS

Tofacitinib-d3 (citrate) is deuterium labeled Tofacitinib (citrate). Tofacitinib citrate is an orally available JAK1/2/3 inhibitor with IC50s of 1, 20, and 112 nM, respectively. Tofacitinib citrate has antibacterial, antifungal and antiviral activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TYK2-IN-11

Cat. No.: HY-144087

TYK2-IN-11 (Compound 5B) is a selective **Tyk-2** inhibitor with IC_{50}s of 0.016 and 0.31 nM for TYK2-JH2 and JAK1-JH2, respectively. TYK2-IN-11 can be used for the research of inflammatory or autoimmune disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TyK2-IN-2

Cat. No.: HY-101762

TyK2-IN-2 (Compoud 18) is a potent and selective **TYK2** inhibitor with IC_{50}s of 7 nM, 0.1 μM and 0.05 μM for **TYK2 JH2**, **IL-23** and **IFNα**, respectively. TyK2-IN-2 also inhibits **phosphodiesterase 4 (PDE4)** with an IC_{50} of 62 nM.



Purity: 99.71%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

Tyk2-IN-3

Cat. No.: HY-18709

Tyk2-IN-3 is a **Tyk2 pseudokinase** inhibitor, with an IC_{50} of 485 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyk2-IN-5

Cat. No.: HY-111745

Tyk2-IN-5 (compound 6) is a highly potent, selective and orally active **Tyk2** inhibitor and targets the JH2 domain, with a K_i of 0.086 nM for Tyk2 JH2 and an IC_{50} of 25 nM for IFNα.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyk2-IN-7

Cat. No.: HY-126242S

Tyk2-IN-7 (Compound 48) is a **TYK2 JH2** inhibitor, binds to TYK2 JH2 domain with IC_{50} and $K_{i.app}$ of 0.00053 μM and 0.00007 μM, respectively.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Tyk2-IN-8

Cat. No.: HY-144031S

Tyk2-IN-8 (Compound 3) is a selective **Tyk-2** inhibitor with an IC_{50} of 5.7 nM for TYK2-JH2. Tyk2-IN-8 inhibits JAK1-JH1 with IC_{50} of 3.0 nM. Tyk2-IN-8 can be used for the research of autoimmune disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tyk2-IN-9

Cat. No.: HY-144032

Tyk2-IN-9 (Compound 26) is a selective **Tyk-2** inhibitor with IC_{50}s of 0.076 and 1.8 nM for TYK2-JH2 and JAK1-JH2, respectively. Tyk2-IN-9 can be used for the research of inflammatory or autoimmune disease.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Upadacitinib

(ABT-494)

Cat. No.: HY-19569

Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (**JAK1**) inhibitor (IC_{50}=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

WHI-P154

Cat. No.: HY-13895

WHI-P154 is a potent **EGFR** inhibitor, and also modestly blocks **JAK3**, with IC_{50}s of 4 nM and 1.8 μM, respectively.



Purity: 99.39%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

WHI-P97

Cat. No.: HY-11067

WHI-P97 is a potent and selective **JAK-3** inhibitor. WHI-P97 is effective in preventing the development allergic asthma in vivo.



Purity: 99.13%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

WP1066

Cat. No.: HY-15312

WP1066 is an inhibitor of **JAK2** and **STAT3**, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

XL019

Cat. No.: HY-13775

XL019 is a potent, orally active, and selective **JAK2** inhibitor, with IC_{50}s of 2.2, 134.3, and 214.2 nM for JAK2, JAK1 and JAK3, respectively.



Purity: ≥98.0%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ZM39923

Cat. No.: HY-12589A

ZM39923 is a **JAK3** inhibitor, with a pIC_{50} of 7.1; ZM39923 also potently inhibits tissue transglutaminase (**TGM2**) with an IC_{50} of 10 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ZM39923 hydrochloride

Cat. No.: HY-12589

ZM39923 hydrochloride is a **JAK3** inhibitor, with a pIC_{50} of 7.1; ZM39923 hydrochloride also potently inhibits tissue transglutaminase (**TGM2**) with an IC_{50} of 10 nM.



Purity: 99.86%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

α7 nAchR-JAK2-STAT3 agonist 1

Cat. No.: HY-146066

α7 nAchR-JAK2-STAT3 agonist 1 is a potent **α7 nAchR-JAK2-STAT3** agonist, with an IC_{50} value of 0.32 μM for **nitric oxide (NO)**. α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pim

Pim kinases

The PIM kinase, also known as serine/threonine kinase plays an important role in cancer biology and is found in three different isoforms namely PIM-1, PIM-2, and PIM-3. Pim kinases are mainly responsible for cell cycle regulation, antiapoptotic activity and the homing and migration of receptor tyrosine kinases mediated via the JAK/STAT pathway.

Pim kinases are over-expressed in various types of tumors and regulate the activation of signaling pathways that are important for tumor cell proliferation, survival and expression of drug efflux proteins. This makes Pim kinases attractive targets for the development of anti-cancer chemotherapeutic drugs.

Pim Inhibitors

(1S,3R,5R)-PIM447 dihydrochloride

((1S,3R,5R)-LGH447 dihydrochloride)

Cat. No.: HY-19322C

(1S,3R,5R)-PIM447 (dihydrochloride) an **PIM** inhibitor extracted from patent US 20100056576 A1, compound example 72, has IC_{50} values of 0.095 μM for Pim1, 0.522 μM for Pim2 and 0.369 μM for Pim3.



Purity: 98.13%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(Z)-SMI-4a

Cat. No.: HY-16576A

(Z)-SMI-4a is a poten, selective, cell-permeable and ATP-competitive **Pim-1** inhibitor with an IC_{50} of 24 μM and a K_i of 0.6 μM. (Z)-SMI-4a also inhibits **Pim-2** (IC_{50} of 100 μM), and does not significantly inhibit the other serine/threonine- or tyrosine-kinases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AZD1208

Cat. No.: HY-15604

AZD1208 is an orally bioavailable, highly selective **PIM** kinases inhibitor.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

AZD1208 hydrochloride

Cat. No.: HY-15604A

AZD1208 hydrochloride is an orally bioavailable, highly selective **PIM** kinases inhibitor.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

CDK6/PIM1-IN-1

Cat. No.: HY-142696

CDK6/PIM1-IN-1 is a potent and balanced dual **CDK6/PIM1** inhibitor with IC_{50} values of 39 and 88 nM, respectively. CDK6/PIM1-IN-1 inhibits CDK4 (IC_{50}=3.6 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CK2/ERK8-IN-1

Cat. No.: HY-135906

CK2/ERK8-IN-1 is a dual **casein kinase 2 (CK2)** (K_i of 0.25 μM) and **ERK8** (MAPK15, ERK7) inhibitor with IC_{50}s of 0.50 μM. CK2/ERK8-IN-1 also binds to **PIM1**, **HIPK2** (**homeodomain-interacting protein kinase 2**), and **DYRK1A** with K_is of 8.65 μM, 15.25 μM, and 11.9 μM, respectively.



Purity: 98.82%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

CK2/PIM1-IN-1

Cat. No.: HY-135816

CK2/PIM1-IN-1 is an inhibitor of **CK2** and **PIM1**, with IC_{50}s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CX-6258

Cat. No.: HY-18095

CX-6258 is a potent and kinase selective **pan-Pim kinases** inhibitor, with IC_{50}s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

CX-6258 hydrochloride

Cat. No.: HY-18095B

CX-6258 hydrochloride is a potent and kinase selective **pan-Pim kinases** inhibitor, with IC_{50}s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

CX-6258 hydrochloride hydrate

Cat. No.: HY-18095A

CX-6258 hydrochloride hydrate is a potent and kinase selective **pan-Pim kinases** inhibitor, with IC_{50}s of 5 nM, 25 nM and 16 nM for Pim-1, Pim-2 and Pim-3, respectively.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

GDC-0339

Cat. No.: HY-16976

GDC-0339 is a potent, orally bioavailable and well tolerated **pan-Pim kinase** inhibitor, with K_is of 0.03 nM, 0.1 nM and 0.02 nM for Pim1, Pim2 and Pim3, respectively. GDC-0339 is discovered as a potential treatment of multiple myeloma.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

GNE-955

Cat. No.: HY-101783

GNE-955 is a potent and orally active pan **Pim kinase** inhibitor with K_is of 0.018, 0.11, 0.08 nM for Pim1, Pim2, Pim3, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Hispidulin

(Dinatin)

Cat. No.: HY-N1950

Hispidulin is a natural flavone with a broad spectrum of biological activities. Hispidulin is a Pim-1 inhibitor with an **IC_{50}** of 2.71 μM.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

M-110

Cat. No.: HY-12830

M-110 is a highly selective, ATP-competitive inhibitor of **PIM kinases** with a preference for **PIM-3** (IC_{50}=47 nM). M-110 inhibits PIM-1 and PIM-2 with similar IC_{50}s of 2.5 μM. M-110 inhibits the proliferation of prostate cancer cell lines with IC_{50}s of 0.6 to 0.9 μM.



Purity: 98.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

MNK/PIM-IN-1

Cat. No.: HY-132867

MNK/PIM-IN-1 represents an innovative dual **MNK/PIM** inhibitor with a good pharmacokinetic profile.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pim-1 kinase inhibitor 2

Cat. No.: HY-147785

Pim-1 kinase inhibitor 2 (Compound 13) is a potent inhibitor of **Pim-1 kinase**. Pim-1 kinase inhibitor 2 induces **apoptosis**. Pim-1 kinase inhibitor 2 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PIM-447 dihydrochloride

(LGH447 dihydrochloride)

Cat. No.: HY-19322B

PIM447 dihydrochloride (LGH447 dihydrochloride) is a potent, orally available, and selective pan-**PIM** kinase inhibitor, with K_i values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 dihydrochloride displays dual antimyeloma and bone-protective effects.



Purity: 99.27%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

PIM-IN-1

Cat. No.: HY-142656

PIM-IN-1 is a pan-PIM kinase inhibitor (KG-1, **EC_{50}** = 61 nM; pS6, **EC_{50}** = **71 nM)**..



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PIM1-IN-1

Cat. No.: HY-111552

PIM1-IN-1 is a potent and highly selective **PIM1/3** inhibitor, with **IC_{50}**s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively, inhibits the phosphorylation of BAD, a downstream target of PIM, with an EC_{50} of 262 nM.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PIM1-IN-2

Cat. No.: HY-108605

PIM1-IN-2 is a potent and ATP competitive **Pim-1** inhibitor with a K_i of 91 nM. PIM1-IN-2 targets the ATP-binding kinase hinge region not by forming classical hydrogen bonds.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PIM1-IN-3

Cat. No.: HY-143897

PIM1-IN-3 (Compound HL8) is a potent inhibitor of **PIM1**. PIM1-IN-3 shows selective inhibition for the PIM-1 enzyme. PIM1-IN-3 induces apoptosis efficiently in Colo320 cells. PIM1-IN-3 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PIM1-IN-4

Cat. No.: HY-143898

PIM1-IN-4 (Compound 8) is a potent inhibitor of **PIM1**. PIM1-IN-4 reveals strong inhibition of five other enzymes, i.e., SGK-1, PKA, CaMK-1, GSK3β, and MSK1. PIM1-IN-4 has the potential for the research of cancer diseases.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pim1/AKK1-IN-1

(LKB1/AAK1 dual inhibitor)

Cat. No.: HY-10371

Pim1/AKK1-IN-1 is a potent multi-kinase inhibitor with K_d values of 35 nM/53 nM/75 nM/380 nM for **Pim1/AKK1/MST2/LKB1** respectively, and also inhibits MPSK1 and TNIK.



Purity: 98.12%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PIM447

(LGH447)

Cat. No.: HY-19322

PIM447 (LGH447) is a potent, orally available, and selective pan-**PIM kinase** inhibitor, with K_i values of 6, 18, and 9 pM for PIM1, PIM2, and PIM3, respectively. PIM447 displays dual antimyeloma and bone-protective effects. PIM447 induces **apoptosis**.



Purity: >98%
Clinical Data: Phase 1
Size: 1 mg, 5 mg

Quercetagetin

(6-Hydroxyquercetin)

Cat. No.: HY-N4149

Quercetagetin (6-Hydroxyquercetin) is a flavonoid. Quercetagetin is a moderately potent and selective, cell-permeable **pim-1** kinase inhibitor (IC_{50}, 0.34 μM). Anti-inflammatory and anticancer properties.



Purity: 99.24%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

R8-T198wt

Cat. No.: HY-P1404

R8-T198wt is a cell-permeable carboxyl-terminal $p27^{Kip1}$ peptide exhibits anti-tumor activity by inhibiting **Pim-1 kinase**.

GGGRRRRRRRRRGCKKPGLRRRQT

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SEL24-B489

Cat. No.: HY-120758

SEL24-B489 is a potent, type I, orally active, dual **PIM** and **FLT3-ITD** inhibitor, with K_d values of 2 nM for PIM1, 2 nM for PIM2 and 3 nM for PIM3, respectively.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SGI-1776

Cat. No.: HY-13287

SGI-1776 is an inhibitor of **Pim** kinases, with IC_{50}s of 7 nM, 363 nM, and 69 nM for Pim-1, -2 and -3, respectively.



Purity: 99.23%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SMI-16a

(PIM1/2 Kinase Inhibitor VI)

Cat. No.: HY-101947

SMI-16a is a selective **Pim** kinase inhibitor with IC_{50} values of 0.15, 0.02 and 48 μM for Pim1, Pim2 and PC3 cells, respectively.



Purity: 99.70%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TCS PIM-1 1

(SC 204330)

Cat. No.: HY-18086

TCS PIM-1 1 (SC 204330) is a potent, selective and ATP-competitive **Pim-1** kianse inhibitor with an IC_{50} of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2 (IC_{50}s >20000 nM).



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

TCS-PIM-1-4a

(SMI-4a) **Cat. No.**: HY-16576

TCS-PIM-1-4a (SMI-4a) is a pan-**Pim** kinases inhibitor that blocks **mTORC1** activity via activation of **AMPK**. TCS-PIM-1-4a kills a wide range of both myeloid and lymphoid cell lines (IC_{50} values ranging from 0.8 μM to 40 μM).



Purity: 99.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

TP-3654

Cat. No.: HY-101126

TP-3654 is a second-generation **Pim** kinase inhibitor with K_i values of 5 and 42 nM for Pim-1 and Pim-3, respectively.



Purity: 99.91%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Uzansertib

(INCB053914) **Cat. No.**: HY-101870

Uzansertib (INCB053914) is an orally active, ATP-competitive pan-**PIM kinase** inhibitor with IC_{50}s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib has broad anti-proliferative activity against a variety of hematologic tumor cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Uzansertib phosphate

(INCB053914 phosphate) **Cat. No.**: HY-101870B

Uzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan-**PIM kinase** inhibitor with IC_{50}s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. Uzansertib phosphate has broad anti-proliferative activity against a variety of hematologic tumor cell lines.



Purity: 98.44%
Clinical Data: Phase 2
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STAT

STAT is a family of cytoplasmic protein that regulates many aspects of growth, survival and differentiation in cells. The transcription factors of this family are activated by Janus kinase and dysregulation of this pathway is frequently observed in primary tumours and leads to increased angiogenesis, enhanced survival of tumours and immunosuppression. Gene knockout studies have provided evidence that STAT proteins are involved in the development and function of the immune system and play a role in maintaining immune tolerance and tumour surveillance. STAT proteins were originally described as latent cytoplasmic transcription factors that require phosphorylation for nuclear retention. The unphosphorylated STAT proteins shuttle between cytosol and the nucleus waiting for its activation signal. Once the activated transcription factor reaches the nucleus, it binds to consensus DNA-recognition motif called gamma-activated sites (GAS) in the promoter region of cytokine-inducible genes and activates transcription of these genes.

(+)-Ochromycinone

(STA-21) Cat. No.: HY-121482

(+)-Ochromycinone is a natural antibiotic that potently inhibits STAT3. (+)-Ochromycinone is used in the researches of cancers and psoriasis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(E/Z)-AG490

((E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42) Cat. No.: HY-107459

(E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a **tyrosine kinase** inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: ≥96.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

(R)-Lisofylline

((R)-Lisophylline) Cat. No.: HY-109854A

(R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 5 mg

1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy) phenyl)urea

Cat. No.: HY-136658

STAT3-IN-7 is a Sorafenib analogue and potently inhibits the phosphorylation of **STAT3**. STAT3-IN-7 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-7 does not inhibit kinase activity and has anticancer effects.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

2-NP

Cat. No.: HY-W013523

2-NP is a selective enhancer of **STAT1** transcription. 2-NP can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

5,15-Diphenylporphyrin

(5,15-DPP) Cat. No.: HY-W035137

5,15-Diphenylporphyrin (5,15-DPP) is a selective **STAT3-SH2** antagonist (IC_{50}s of 0.28 μM and 10 μM for STAT3 and STAT1, respectively).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AC-4-130

Cat. No.: HY-124500

AC-4-130 is a potent **STAT5 SH2** domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription.



Purity: 99.87%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

ACT001

Cat. No.: HY-128861A

ACT001 is an orally active **PAI-1** inhibitor by inhibiting the phosphorylation of **PI3K** and **AKT**. ACT001 inhibits the phosphorylation of STAT3 and PD-L1 expression by directly binding to **STAT3**.



Purity: 99.62%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

AG490

(Tyrphostin AG490; Tyrphostin B42) Cat. No.: HY-12000

AG490 (Tyrphostin AG490) is a tyrosine kinase inhibitor that inhibits **EGFR**, **Stat-3** and **JAK2/3**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Alantolactone

((+)-Alantolactone; Alant camphor; Inula camphor) Cat. No.: HY-N0038

Alantolactone is a selective **STAT3** inhibitor, with potent anticancer activity. Alantolactone induces apoptosis in cancer.



Purity: 99.94%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Angoline

Cat. No.: HY-N7674

Angoline is a potent and selective **IL6/STAT3 signaling pathway** inhibitor with an IC_{50} of 11.56 μM. Angoline inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 5 mg

Angoline hydrochloride

Cat. No.: HY-N7674A

Angoline hydrochloride is a potent and selective **IL6/STAT3 signaling pathway** inhibitor with an IC_{50} of 11.56 μM. Angoline hydrochloride inhibits STAT3 phosphorylation and its target gene expression, and inhibits cancer cell proliferation.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

APTSTAT3-9R

Cat. No.: HY-P2282

APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking **STAT3** phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Arnicolide D

Cat. No.: HY-N6843

Arnicolide D is a sesquiterpene lactone isolated from Centipeda minima. Arnicolide D modulates the cell cycle, activates the **caspase** signaling pathway and inhibits the **PI3K/AKT/mTOR** and **STAT3** signaling pathways.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Artesunate

Cat. No.: HY-N0193

Artesunate is an inhibitor of both **STAT-3** and **exported protein 1** (**EXP1**).



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

Artesunate-d3

Cat. No.: HY-N0193S

Artesunate-d3 is the deuterium labeled Artesunate. Artesunate is an inhibitor of both **STAT-3** and **exported protein 1** (**EXP1**).



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mg

Artesunate-d4

Cat. No.: HY-N0193S1

Artesunate-d4 is deuterium labeled Artesunate. Artesunate is an inhibitor of both STAT-3 and exported protein 1 (EXP1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AS1517499

Cat. No.: HY-100614

AS1517499 is a potent and brain-permeable **STAT6** phosphorylation inhibitor with an IC_{50} of 21 nM.



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS1810722

Cat. No.: HY-134772

AS1810722 is an orally active and potent **STAT6** inhibitor with an IC_{50} of 1.9 nM. AS1810722 shows a good profile of **CYP3A4** inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.



Purity: 98.56%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AS2863619

Cat. No.: HY-126675A

AS2863619 enables conversion of antigen-specific effector/memory T cells into Foxp3$^+$ regulatory T (T_{reg}) cells for the treatment of various immunological diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AS2863619 free base

Cat. No.: HY-126675

AS2863619 free base enables conversion of antigen-specific effector/memory T cells into Foxp3$^+$ regulatory T (T_{reg}) cells for the treatment of various immunological diseases.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Ascochlorin

(Ilicicolin D)

Cat. No.: HY-101021

Ascochlorin (Ilicicolin D), an isoprenoid antibiotic, mediates its anti-tumor effects predominantly through the suppression of **STAT3** signaling cascade. Ascochlorin induces **apoptosis**. Anti-inflammatory activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Atractylenolide I

Cat. No.: HY-N0201

Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Balsalazide

Cat. No.: HY-B0667

Balsalazide could suppress colitis-associated carcinogenesis through modulation of **IL-6/STAT3** pathway.



Purity: 99.20%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Balsalazide sodium hydrate

(Balsalazide disodium dihydrate)

Cat. No.: HY-B0667A

Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of **IL-6/STAT3** pathway.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Balsalazide-d4

Cat. No.: HY-B0667S1

Balsalazide-d4 is deuterium labeled Balsalazide. Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

BD750

Cat. No.: HY-131140

BD750, an effective immunosuppressant and a **JAK3/STAT5** inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation, with IC_{50} values of 1.5 μM and 1.1 μM in mouse and human T cells, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

BP-1-102

Cat. No.: HY-100493

BP-1-102 is an orally available, small-molecule inhibitor of transcription factor **Stat3**, with an IC_{50} of 6.8 μM.



Purity: 98.98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Brevilin A

Cat. No.: HY-N2959

Brevilin A is a sesquiterpene lactone isolated from Centipeda minima with anti-tumor activity. Brevilin A is a selective inhibitor of **JAK-STAT** signal pathway by attenuating the JAKs activity and blocking STAT3 signaling (IC_{50} = 10.6 μM) in Cancer Cells.



Purity: 99.77%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

C188

(CPD188)

Cat. No.: HY-112338

C188 is a **STAT3** inhibitor that inhibits IL-6-stimulated STAT3 phosphorylation and nuclear translocation in HepG2 cells by targeting STAT3 SH2 domain peptide-binding pocket.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

C188-9

(TTI-101) Cat. No.: HY-112288

C188-9 (TTI-101) is a **STAT3** inhibitor, with a K_d of 4.7 nM. C188-9 inhibits G-CSF-induced STAT3 activation and STAT3-dependent gene expression. C188-9 induces **apoptosis** in AML cell lines and primary samples and inhibits colony formation by primary AML blasts.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Casticin

(Vitexicarpin) Cat. No.: HY-N0516

Casticin is a methyoxylated flavonol isolated from Viticis Fructus, with antimitotic and anti-inflammatory effect. Casticin inhibits the activation of **STAT3**.



Purity: 99.67%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Cenisertib

(AS-703569; R-763) Cat. No.: HY-13072

Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of **Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3**.



Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Cirsilineol

Cat. No.: HY-119347

Cirsilineol, a natural flavone compound, selectively inhibits IFN-γ/STAT1/T-bet signaling in intestinal $CD4^+$ T cells. Cirsilineol has potent immunosuppressive and anti-tumor properties.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMD178

Cat. No.: HY-P1453

CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling. CMD178 also is an inhibitor of STAT5 and inhibit T_{reg} cell development.

RFKF[Y(OBn)]

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMD178 TFA

Cat. No.: HY-P1453A

CMD178 (TFA) is a lead peptide that consistently reduces the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling. CMD178 (TFA) also is an inhibitor of **STAT5** and inhibits T_{reg}cells development.

RFKF[Y(OBn)]



Purity: 98.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Colivelin

Cat. No.: HY-P1061

Colivelin is a brain penetrant **neuroprotective peptide** and a potent activator of **STAT3**, suppresses neuronal death by activating STAT3 in vitro.

SALLRSIPAPAGASRLLLLTGEIDLP

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Colivelin TFA

Cat. No.: HY-P1061A

Colivelin TFA is a brain penetrant **neuroprotective peptide** and a potent activator of **STAT3**, suppresses neuronal death by activating STAT3 in vitro.

SALLRSIPAPAGASRLLLLTGEIDLP (TFA salt)

Purity: 99.22%
Clinical Data: No Development Reported
Size: 500 μg, 1 mg

Corylifol A

(Corylifol-A; Corylinin) Cat. No.: HY-N0897

Corylifol A inhibits IL-6-induced **STAT3** activation and phosphorylation, with an IC_{50} of 0.81 μM.



Purity: 99.75%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Cryptotanshinone

(Cryptotanshinon; Tanshinone c) Cat. No.: HY-N0174

Cryptotanshinone is a natural compound extracted from the root of Salvia miltiorrhiza Bunge that shows antitumor activities. Cryptotanshinone inhibits **STAT3** with an IC_{50} of 4.6 μM.



Purity: 98.69%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Cucurbitacin I

(Elatericin B; JSI-124; NSC-521777) Cat. No.: HY-N1405

Cucurbitacin I is a natural selective inhibitor of **JAK2/STAT3**, with potent anti-cancer activity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Curculigoside

Cat. No.: HY-N0705

Curculigoside is the main saponin in C. orchioide, exerts significant antioxidant, anti-osteoporosis, antidepressant and neuroprotection effects. Curculigoside possesses significant anti-arthritic effects in vivo and in vitro via regulation of the **JAK/STAT/NF-κB** signaling pathway.



Purity: 99.73%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Danvatirsen

(AZD 9150) Cat. No.: HY-145729

Danvatirsen is an antisense oligonucleotide targeting **STAT3** with potential antitumor activity. Danvatirsen binds to STAT3 mRNA, thereby inhibiting translation of the transcript. Suppression of STAT3 expression induces tumor cell apoptosis and decreases tumor cell growth.

Danvatirsen

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Debio 0617B

Cat. No.: HY-108417

Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML $CD34^+$ stem/progenitor cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Delphinidin chloride

Cat. No.: HY-N2409

Delphinidin chloride, an anthocyanidin, is isolated from berries and red wine. Delphinidin chloride shows endothelium-dependent vasorelaxation. Delphinidin chloride also can modulate JAK/STAT3 and MAPKinase signaling to induce apoptosis in HCT116 cells.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Dihydroisotanshinone I

Cat. No.: HY-B1919

Dihydroisotanshinone I, a bioactive compound present in danshen, can inhibit the migration of both androgen-dependent and androgen-independent prostate cancer cells. Dihydroisotanshinone I also induces **apoptosis** and **ferroptosis** in these lung cancer cells.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Diosgenin

Cat. No.: HY-N0177

Diosgenin, a steroidal saponin, can inhibit **STAT3** signaling pathway. Diosgenin is an exogenous activator of **Pdia3/ERp57**.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 100 mg

ENMD-1198

(IRC-110160) Cat. No.: HY-16196

ENMD-1198 (IRC-110160), an orally active **microtubule destabilizing** agent, is a 2-methoxyestradiol analogue with antiproliferative and antiangiogenic activity.



Purity: 98.87%
Clinical Data: No Development Reported
Size: 1 mg

Eupalinolide K

Cat. No.: HY-N2240

Eupalinolide K, a sesquiterpene lactones compound from Eupatorium lindleyanum, is a **STAT3** inhibitor. Eupalinolide K is a Michael reaction acceptor (MRA) .



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

FLLL32

Cat. No.: HY-100544

FLLL32, a synthetic analog of curcumina, is a **JAK2/STAT3** dual inhibitor with anti-tumor activity. FLLL32 can inhibit the induction of STAT3 phosphorylation by IFNα and IL-6 in breast cancer cells.



Purity: 99.78%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Fludarabine

(F-ara-A; NSC 118218)

Cat. No.: HY-B0069



Fludarabine (NSC 118218) is a **DNA synthesis** inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies.

Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Fraxinellone

Cat. No.: HY-N0242



Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a **PD-L1** inhibitor and inhibits **HIF-1α** protein synthesis without affecting HIF-1α protein degradation.

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Galiellalactone

Cat. No.: HY-125170



Galiellalactone is a is a small non-toxic and non-mutagenic fungal metabolite, a selective inhibitor of **STAT3 signaling**, with an IC_{50} of 250-500 nM. Galiellalactone can be used to research castration-resistant prostate cancer.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Garcinone C

Cat. No.: HY-N6954



Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia Champ that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers.

Purity: 99.66%
Clinical Data: No Development Reported
Size: 1 mg

Garcinone D

Cat. No.: HY-N6953



Garcinone D, a natural xanthone from mangosteen, promotes the proliferation of C17.2 neural stem cell.

Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg

Golotimod

(SCV 07; Gamma-D-glutamyl-L-tryptophan)

Cat. No.: HY-14743



Golotimod (SCV-07), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.

Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Golotimod hydrochloride (SCV 07 hydrochloride; Gamma-D-glutamyl-L-tryptophan hydrochloride)

Cat. No.: HY-14743B



Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.

Purity: 98.90%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Golotimod TFA

(SCV 07 TFA; Gamma-D-glutamyl-L-tryptophan TFA)

Cat. No.: HY-14743A



Golotimod TFA (SCV 07 TFA), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HJC0152 hydrochloride

Cat. No.: HY-100602



HJC0152 hydrochloride is a **signal transducers and activators of transcription 3** (**STAT3**) inhibitor.

Purity: 98.95%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

HJC0416 hydrochloride

Cat. No.: HY-12352A



HJC0416 hydrochloride is a potent and orally active **STAT3** inhibitor with an enhanced anticancer profile than Stattic (HY-13818). HJC0416 hydrochloride is a promising anti-cancer agent for breast cancer study.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

HO-3867

Cat. No.: HY-100453

HO-3867 is a selective and potent **STAT3** inhibitor and shows good antitumor activity.



Purity: 98.26%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Homoharringtonine

(Omacetaxine mepesuccinate; HHT)

Cat. No.: HY-14944

Homoharringtonine (Omacetaxine mepesuccinate;HHT) is a cytotoxic alkaloid with antitumor properties which acts by inhibiting **translation elongation**.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

inS3-54A18

Cat. No.: HY-103128

inS3-54A18 is a potent **STAT3** inhibitor, with anti-cancer properties.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

L002

Cat. No.: HY-100671

L002 is a potent, cell permeable, reversible and specific **acetyltransferase p300 (KAT3B)** inhibitor with an IC_{50} of 1.98 μM.



Purity: 98.80%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MM-206

Cat. No.: HY-121725

MM-206, a **STAT3** activity inhibitor, potently inhibits the STAT3 SH2 domain-phosphopeptide interaction with IC_{50} of 1.2 μM. MM-206 demonstrates dose-dependent induction of apoptosis in acute myeloid leukemia (AML) cell lines.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Mogrol

Cat. No.: HY-N2312

Mogrol is a biometabolite of mogrosides, and acts via inhibition of the **ERK1/2** and **STAT3** pathways, or reducing **CREB** activation and activating **AMPK** signaling.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg

Morusin

(Mulberrochromene)

Cat. No.: HY-N0622

Morusin is a prenylated flavonoid isolated from M. australis with various biological activities, such as antitumor, antioxidant, and anti-bacteria property. Morusin could inhibit **NF-κB** and **STAT3** activity.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg

Napabucasin

(BBI608)

Cat. No.: HY-13919

Napabucasin (BBI608) is a **STAT3** inhibitor which blocks stem cell activity in cancer cells.



Purity: 99.27%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Niclosamide

(BAY2353)

Cat. No.: HY-B0497

Niclosamide (BAY2353) is an orally bioavailable chlorinated salicylanilide, with anthelmintic and potential antineoplastic activity. Niclosamide (BAY2353) inhibits **STAT3** with IC_{50} of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.



Purity: 98.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 500 mg, 5 g, 10 g

Niclosamide monohydrate

(BAY2353 monohydrate)

Cat. No.: HY-B0497B

Niclosamide monohydrate is an inhibitor of **STAT3** with IC_{50} of 0.25 μM in HeLa cells and inhibits DNA replication in a cell-free assay.



Purity: >98%
Clinical Data: Launched
Size: 500 mg

Niclosamide olamine

(BAY2353 olamine)

Cat. No.: HY-B0497C

Niclosamide olamine (BAY2353 olamine) is an anthelmintic that disrupts mitochondrial metabolism in parasitic worms and animal models.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Nifuroxazide

Cat. No.: HY-B1436

Nifuroxazide is an effective inhibitor of **STAT3**, also exerts potent anti-tumor and anti-metastasis activity.



Purity: 98.55%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg

Nifuroxazide-d4

Cat. No.: HY-B1436S

Nifuroxazide-d4 is the deuterium labeled Nifuroxazide. Nifuroxazide is an effective inhibitor of **STAT3**, also exerts potent anti-tumor and anti-metastasis activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Nitidine chloride

Cat. No.: HY-N0498

Nitidine chloride, a potential **anti-malarial** lead compound derived from Zanthoxylum nitidum (Roxb) DC, exerts potent anticancer activity through diverse pathways, including inducing **apoptosis**, inhibiting **STAT3** signaling cascade, **DNA topoisomerase 1 and 2A**, **ERK** and...



Purity: 99.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 20 mg

NSC 74859

(S3I-201)

Cat. No.: HY-15146

NSC 74859 (S3I-201) is a selective **Stat3** inhibitor with an IC_{50} of 86 μM.



Purity: 98.64%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

NT219

Cat. No.: HY-145935

NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (**IRS1/2**) and **STAT3**. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ochromycinone

((Rac)-STA-21)

Cat. No.: HY-18061

Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a **STAT3** inhibitor. Ochromycinone can inhibits **STAT3** DNA binding activity, **STAT3** dimerization. Ochromycinone has anticancer and antimicrobial activity.



Purity: 99.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Picroside I

(6'-Cinnamoylcatalpol)

Cat. No.: HY-N0407

Picroside I is the major ingredient of Picrorhiza kurroa. Picrorhiza kurroa is a high value medicinal herb due to rich source of hepatoprotective metabolites, Picroside-I and Picroside-II. Picroside I is a promising agent for the management of asthma.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Pimozide

(R6238)

Cat. No.: HY-12987

Pimozide is a **dopamine receptor** antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at **α1-adrenoceptor**, with a K_i of 39 nM; Pimozide also inhibits **STAT3** and **STAT5**.



Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg

Pimozide-d4

(R6238-d4)

Cat. No.: HY-12987S

Pimozide D4 (R6238 D4) is a deuterium labeled Pimozide.



Purity: >98%
Clinical Data: Phase 4
Size: 1 mg, 5 mg

Pimozide-d5 N-Oxide

Cat. No.: HY-12987S1

Pimozide-d5 N-Oxide is the deuterium labeled Pimozide.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Protosappanin A

(PTA)

Cat. No.: HY-113573

Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses **JAK2/STAT3**-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.



Purity: 99.98%
Clinical Data:
Size: 1 mg, 5 mg, 10 mg

Reticuline

Cat. No.: HY-N1356

Reticuline shows anti-inflammatory effects through **JAK2/STAT3** and **NF-κB** signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3. Reticuline exhibits cardiovascular effects.



Purity: 98.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Reticuline-d3

Cat. No.: HY-N1356S

Reticuline-d3 is the deuterium labeled Reticuline. Reticuline shows anti-inflammatory effects through **JAK2/STAT3** and **NF-κB** signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

RO8191

(CDM-3008; RO4948191)

Cat. No.: HY-W063968

RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent **interferon (IFN) receptor** agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and **JAK/STAT** phosphorylation.

Purity: 98.53%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

RSVA405

Cat. No.: HY-103238

RSVA405 is a potent, orally active activator of **AMPK**, with an EC_{50} of 1 μM. RSVA405 facilitates CaMKKβ-dependent activation of AMPK, inhibits **mTOR**, and promotes **autophagy** to increase Aβ degradation.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Saikosaponin D

Cat. No.: HY-N0250

Saikosaponin D is a triterpene saponin isolated from Bupleurum, with anti-inflammatory, anti-bacterial, anti-tumor, and anti-allergic activities; Saikosaponin D inhibits **selectin**, **STAT3** and **NF-kB** and activates **estrogen receptor-β**.



Purity: 98.76%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SC-43

Cat. No.: HY-136657

SC-43, a Sorafenib derivative, is a potent and orally active **SHP-1 (PTPN6)** agonist. SC-43 inhibits the phosphorylation of **STAT3** and induces cell **apoptosis**. SC-43 has anti-fibrotic and anticancer effects.



Purity: 98.61%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SC99

Cat. No.: HY-124858

SC99 is an orally active, selective **STAT3** inhibitor targeting JAK2-STAT3 pathway. SC99 docks into the ATP-binding pocket of JAK2. SC99 inhibits phosphorylation of JAK2 and STAT3 with no effects on the other kinases associated with STAT3 signaling.



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Scutellarin

Cat. No.: HY-N0751

Scutellarin, an active flavone isolated from Scutellaria baicalensis, can down-regulates the **STAT3/Girdin/Akt** signaling in HCC cells, and inhibits RANKL-mediated **MAPK and NF-κB** signaling pathway in osteoclasts.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg

SD-1008

Cat. No.: HY-107595

SD-1008 is a potent **JAK** inhibitor. SD-1008 inhibits tyrosyl phosphorylation of STAT3, JAK2 and Src. SD-1008 also reduces STAT3-dependent luciferase activity. SD-1008 enhances **apoptosis** induced by Paclitaxel in ovarian cancer cells via directly blocking the JAK-STAT3 signaling pathway.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SD-1029

Cat. No.: HY-112391

SD-1029 is a **JAK2/STAT3** inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SD-36

Cat. No.: HY-129602

SD-36 is a potent and efficacious **STAT3** PROTAC degrader (K_d=~50 nM), and demonstrates high selectivity over other STAT members. SD-36 also effectively degrades mutated STAT3 proteins in cells and suppresses the transcriptional activity of STAT3 (IC_{50}=10 nM).



Purity: 99.46%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

SH-4-54

Cat. No.: HY-16975

SH-4-54 is a **STAT** inhibitor that binds to STAT3 and STAT5 with K_D**s** of 300, 464 nM, respectively.



Purity: 99.59%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

SH5-07

Cat. No.: HY-100494

SH5-07 is a hydroxamic acid based **Stat3** inhibitor with an IC_{50} of 3.9 μM in in vitro assay.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SI-109

Cat. No.: HY-129603

SI-109 is a potent **STAT3 SH2 domain** inhibitor (K_i=9 nM) with antitumor activity. SI-109 effectively inhibits the transcriptional activity of STAT3 (IC_{50}=3 μM). SI-109 and an analog of CRBN ligand lenalidomide have been used to design PROTAC STAT3 degrader **SD-36**.



Purity: 99.48%
Clinical Data: No Development Reported
Size: 5 mg

Stafia-1

Cat. No.: HY-136546

Stafia-1 is a potent **STAT5a** inhibitor (K_i=10.9 μM, IC_{50}=22.2 μM). Stafia-1 displays high selectivity over STAT5b and other STAT family members.



Purity: 99.53%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Stafia-1-dipivaloyloxymethyl ester

Cat. No.: HY-136568

Stafia-1-dipivaloyloxymethyl ester (compound 27, 0-200 μM) decreases pSTAT5a expression significantly, and has no obvious inhibition on pSTAT5b.



Purity: 98.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Stafib-1

Cat. No.: HY-112647

Stafib-1 is the first selective inhibitor of the **STAT5b SH2** domain, with a K_i of 44 nM and an IC_{50} of 154 nM.



Purity: 95.04%
Clinical Data: No Development Reported
Size: 5 mg

Stafib-2

Cat. No.: HY-112648

Stafib-2 is a potent and selctive inhibitor of the **transcription factor STAT5b**, with an IC_{50} of 82 nM and 1.7 μM for **STAT5b** and **STAT5a**, respectively. Stafib-2 exhibits poor cell permeability.



Purity: 95.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STAT3-IN-1

Cat. No.: HY-100753

STAT3-IN-1 (compound 7d) is an excellent, selective and orally active **STAT3** inhibitor, with IC_{50} values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor apoptosis.



Purity: 96.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

STAT3-IN-10

Cat. No.: HY-146728

STAT3-IN-10 (A11) is a **STAT3** inhibitor with an IC_{50} value of 5.18 μM. STAT3-IN-10 directly binds to STAT3 SH2 domain, inhibits tumor cell growth and induces **apoptosis** in cancer cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STAT3-IN-3

Cat. No.: HY-128588

STAT3-IN-3 is a potent and selective inhibitor of **signal transducer and activator of transcription 3 (STAT3)**, with anti-proliferative activity. STAT3-IN-3 induces **apoptosis** in breast cancer cells.



Purity: 98.23%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STAT3-IN-7

Cat. No.: HY-144870

STAT3-IN-7, an aryl sulfonamido azetidine compound, is an orally active **STAT3** inhibitor. STAT3-IN-7 has anticancer activities (WO2021016333A1, H182).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STAT3-IN-8

Cat. No.: HY-144871

STAT3-IN-8 (compound H172) is a potent **STAT3** inhibitor. STAT3-IN-8 has the potential for cancer research.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

STAT5-IN-1

Cat. No.: HY-101853

STAT5-IN-1 is a **STAT5** inhibitor with an IC_{50} of 47 μM for STAT5β isoform.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

STAT5-IN-2

Cat. No.: HY-102048

STAT5-IN-2 is a **STAT5** inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect.



Purity: 99.01%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Stattic

Cat. No.: HY-13818

Stattic is a potent **STAT3** inhibitor and inhibits STAT3 phosphorylation (at Y705 and S727). Stattic inhibits the binding of a high affinity phosphopeptide for the SH2 domain of STAT3. Stattic ameliorates the renal dysfunction in Alport syndrome (AS) mice.



Purity: ≥97.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 25 mg, 50 mg, 100 mg

Tetramethylcurcumin

(FLLL31)

Cat. No.: HY-N2521

Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of **STAT3** by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects.



Purity: 99.91%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

TPCA-1

Cat. No.: HY-10074

TPCA-1 is a potent and selective inhibitor of **IKK-2** with IC_{50} of 17.9 nM. TPCA-1 is an effective inhibitor of **STAT3** phosphorylation, DNA binding, and transactivation.



Purity: 99.66%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Triacetylresveratrol

Cat. No.: HY-N1410

Triacetylresveratrol, an acetylated analog of Resveratrol. Triacetylresveratrol decreases the phosphorylation of **STAT3** and **NF-κB** in a dose- and time- dependent manner in PANC-1 and BxPC-3 cells. Anticancer effects.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg

UC-514321

Cat. No.: HY-120395

UC-514321, a structural analog of NSC370284 with higher activity, directly targets **STAT3/5** and represses **TET1** expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

WP1066

Cat. No.: HY-15312

WP1066 is an inhibitor of **JAK2** and **STAT3**, and also shows effect on STAT5 and ERK1/2, without affecting JAK1 and JAK3.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 10 mg, 50 mg

YM-341619

(AS1617612)

Cat. No.: HY-134771

YM-341619 (AS1617612) is a potent and orally active **STAT6** inhibitor with an $\mathbf{IC_{50}}$ of 0.70 nM. YM-341619 inhibits Th2 differentiation in mouse spleen T cells induced by IL-4 ($\mathbf{IC_{50}}$=0.28 nM) without affecting Th1 cell differentiation.



Purity: ≥95.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

α7 nAchR-JAK2-STAT3 agonist 1

Cat. No.: HY-146066

α7 nAchR-JAK2-STAT3 agonist 1 is a potent **α7 nAchR-JAK2-STAT3** agonist, with an $\mathbf{IC_{50}}$ value of 0.32 μM for **nitric oxide (NO)**. α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg